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ABSTRACT 
Propionic acidemia (PA) is a rare inborn error of metabolism (IBEM) identifiable by newborn 
screening (NBS). PA patients have variable clinical presentations and neonatal symptomology 
can be severe and potentially life threatening. Longitudinal data is being collected to learn more 
about the natural history of PA and current management of these patients.  As care 
recommendations are being developed, it is important to understand patients’ service utilization 
and current unmet needs.  
This study describes the PA patient data from the Inborn Errors of Metabolism 
Information System (IBEM-IS), a database created to follow patients with conditions detected or 
detectable by NBS. Data from 46 PA subjects and 137 visits entered into IBEM-IS were 
analyzed for anticipated needs of PA patients based on the clinical spectrum and current 
published practice guidelines. Analysis of PA data in IBEM-IS revealed that the majority of the 
desired variables were absent. Thus, precise determination of service utilization by PA patients 
remains incomplete. There remains a need for comprehensive, uniform data collection and more 
detailed assessment of patients. 
The original design of the study incorporated an interview of parents/guardians of PA 
patients to identify current service utilization for comparison to aggregate data in IBEM-IS. Due 
to recruitment challenges, two of three aims of this study were not achieved. The difficulties 
experienced with recruitment and collaborative work with a multi-center consortium are 
discussed.  
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This analysis of PA patient data in IBEM-IS augments the database and promotes future 
research studies. Learning more about service utilization and parents’ perceived unmet needs for 
PA patients may also have implications for a broader group of IBEM identifiable by NBS. 
Further, the need to prove efficacy of NBS, as a public health program intended to decrease 
morbidity and mortality, can be supported by this analysis of outcomes and patients needs in 
those identified by NBS and those identified clinically. The improved long-term care and follow 
up resulting from focused research on current practices and needs in these patients will impact 
many individuals and their families.   
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1.0  INTRODUCTION 
Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism. PA is a rare 
organic acid disorder with an estimated worldwide incidence ranging from 1 in 300,000 to 1 in 
165,000 live births. Mutations in either the PCCA or PCCB gene cause PA and lead to an 
accumulation of organic acids in the blood, urine, and tissue. The abnormal build-up of organic 
acids is toxic and can be life-threatening. Acute manifestations of PA such as vomiting, poor 
feeding, and lethargy can be observed shortly after birth in affected individuals and also later in 
life during times of metabolic crisis brought on by catabolic stressors. If these symptoms are left 
untreated seizures, and in some cases coma and death, can occur. Chronic manifestations of PA 
include failure to thrive, developmental delay, vomiting, protein intolerance, neurological 
manifestations including seizures, MRI abnormalities and intellectual disability and heart 
complications such as cardiomyopathy and cardiac rhythm abnormalities (Pena and Burton 
2012).  
Early diagnosis of PA had been associated with a lower mortality rate. However, a study 
done by Grünert et al. in 2012 compared the overall clinical outcomes of 20 PA patients who 
were diagnosed through newborn bloodspot screening (NBS) to 35 patients who were diagnosed 
by a selective metabolic screen because of clinical presentation or family history. The study did 
not find a significant difference between the two groups. There was little difference with regard 
to their clinical course, including the number of metabolic crises, physical and neurocognitive 
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development, and long-term complications (Grunert, Mullerleile et al. 2012). While early 
detection of PA is important, the current management and treatment of individuals affected with 
PA, even if initiated promptly, may not be significantly improving the patient’s quality of life.  
Due to the low incidence and heterogeneity of the condition, there were previously no 
clear guidelines for the medical management of patients with PA. To establish a standardized list 
of practice guidelines, the Children's National Medical Center in Washington, D.C. convened a 
group of healthcare professionals, researchers, and parents in January 2011. At the time of this 
meeting and in the published proceedings, it was acknowledged that there had only been limited 
improvement in understanding of the natural history of PA through collaborative studies to date. 
Additionally, it was stated that the handful of larger studies were limited by a lack of uniformity 
in data collection (Sass, Hofmann et al. 2004, Chapman and Summar 2012). 
The Inborn Errors of Metabolism Collaborative (IBEMC) is a group of clinicians and 
research coordinators working together to compile information on patients who have one of the 
conditions detected or detectable by newborn screening (NBS). IBEMC created a multi-center 
database to follow and study patients with inborn errors of metabolism, called the Inborn Errors 
of Metabolism Information System (IBEM-IS). This resource was developed in recognition of 
the need to understand more about the natural history and clinical outcomes for patients with rare 
inborn errors of metabolism and to promote future studies and additional research (Berry, Jurek  
et al. 2010).  
This present study assesses the PA subject data present in IBEM-IS to explore 
completeness of patient-specific content and individual and compiled healthcare utilization. To 
date, there has been insufficient data gathered from these patients and families regarding this 
information (Chapman and Summar 2012). Understanding what services PA patients and their 
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families are using and identifying potential unmet needs is important in the development of 
effective management and treatment protocols to improve clinical outcomes and quality of life. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
2.1 HYPOTHESIS 
Hypothesis 1: The differences between the two sets of service utilization data collected 
(database vs. interviews) are due to patients accessing but not disclosing more services than are 
documented in IBEM-IS. Patients may find it difficult to communicate all or unmet service 
needs in the clinic setting, thus requiring more thorough assessment of needs through targeted 
questioning by healthcare professionals. 
Hypothesis 2: The differences between the two sets of service utilization data collected are due 
to the current data collection and entry practices associated with IBEM-IS. 
2.2 SPECIFIC AIMS 
Aim 1: To analyze the service utilization data collected within the IBEM-IS patient registry as 
compared to anticipated needs based on the clinical spectrum of propionic academia (PA). 
Aim 2: To interview parents/guardians of PA patients to identify current service utilization and 
unmet needs. 
Aim 3: To compare parent/guardian stated service utilization to documented aggregate data in 
the IBEM-IS.  
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3.0  BACKGROUND AND SIGNIFICANCE 
3.1 PROPIONIC ACIDEMIA 
Propionic acidemia (PA) was first described by Dr. Barton Childs and his colleagues at Johns 
Hopkins Hospital in 1961 (Childs, Nyhan et al. 1961). PA is a rare, autosomal recessive inborn 
error of metabolism with an estimated worldwide incidence ranging from 1 in 300,000 to 1 in 
165,000 live births (Pena and Burton 2012). PA can be found in individuals of all races and 
ethnicities. However, the condition appears to be more common in the Inuit population of 
Greenland, as well as in Japan, Saudi Arabia, and some Amish communities. With the 
implementation of NBS and tandem mass spectrometry, variability in the frequency of PA 
among countries has been observed. The disease frequency is reported to be 1 in 1000 in the 
Greenland Inuit, 1 in 17,400 in Japan, 1 in 27,264 in Saudi Arabia, 1 in 129,000 in the United 
States, and 1 in 250,000 in Germany (Desviat, Pérez et al. 2004).  
3.1.1 Molecular Basis 
Biallelic mutations in either the PCCA gene, located on chromosome 13q32.3, or the PCCB 
gene, located on chromosome 3q22.3, cause PA (Perez-Cerda, Merinero et al. 2000). The PCCA 
and PCCB genes work to encode the α and β subunits of the mitochondrial enzyme propionyl-
CoA carboxylase (PCC). The enzyme is a heterododecamer of six α subunits and six β subunits 
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(Perez-Cerda, Merinero et al. 2000). PCC catalyzes the conversion of propionyl-CoA to D-
methylmalonyl-CoA, which eventually enters the Krebs cycle as succinyl-CoA (Ugarte, Perez-
Cerda et al. 1999). The function of PCC in the body is to play a role in the catabolism of 
isoleucine, threonine, methionine, and valine, odd-numbered-chained fatty acids, cholesterol, and 
other metabolites (Tahara, Kraus et al. 1993, Magdalena, Celia et al. 1999). Deficiency of the 
PCC enzyme results in an accumulation of propionic acid, free organic acids, and ammonia in 
the blood, urine, and tissue (Pena, Franks et al. 2012). 
3.1.2 Clinical Manifestations 
The clinical picture of PA is variable and natural history of the disorder is still being studied and 
understood.  In a study done by Pena et al. in 2012, a survey of Propionic Acidemia Foundation 
(PAF) members was used for a cross-sectional retrospective review. The responses from 58 
individuals were assessed to determine the frequency of reported complications. Seizures were 
reported as one of the most common complications, occurring in 41% of individuals. Nineteen 
percent of responders reported having cardiomyopathy, which occurred primarily in school-age 
children and adults, and was reported to be the cause of death in 70% of deceased patients (Pena 
and Burton 2012). A retrospective study done by Grünert et al. in 2013 examined the clinical 
outcome data of 55 PA patients from 16 European metabolic centers. Within the study cohort, 
over 85% of the patients had metabolic decompensation during the neonatal period and 75% had 
mental retardation with a median IQ of 55. Other clinical manifestations in their study population 
included hematologic abnormalities, cardiac diseases, feeding problems, and impaired growth 
(Grünert, Müllerleile et al. 2013).  
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In the majority of PA cases, symptoms appear within a few hours or days after birth. 
Nonspecific findings such as poor feeding, vomiting, hypotonia, and lethargy are often the first 
clinical features that are observed. More serious medical concerns, including heart abnormalities 
and neurological complications may occur. PA is classified as an intoxication-type disorder of 
organic acid metabolism and is characterized by the build-up of propionic acid resulting in 
episodes of vomiting, dehydration, and severe metabolic acidosis. The health status of PA 
patients worsens during times of increased metabolic demand. Episodes of fever, infection, 
vomiting, trauma, and psychological or physiological stress can precipitate metabolic acidosis in 
individuals with PA. It is thought that at times concurrent with catabolic stressors, affected 
individuals have higher metabolic rates than they can tolerate and therefore require acute 
management to diminish morbidity and mortality. (Chapman, Gropman et al. 2012). Symptoms 
of metabolic decompensation may include poor feeding, lethargy, failure to thrive, vomiting, and 
potentially coma and death if left untreated. 
Individuals with PA are at risk for developing heart complications including 
cardiomyopathy and arrhythmias. Cardiomyopathy is a common, long-term complication of PA. 
It may resolve with time or progress to cardiac failure (Dionisi-Vici, Deodato et al. 2006). 
Several fatal cases of cardiomyopathy in PA patients have been reported (Mardach, Verity et al. 
2005). However, the age of diagnosis of PA, level of metabolic control, or amount of residual 
enzymatic activity do not seem to correlate with the risk for cardiomyopathy (Pena, Franks et al. 
2012). One recognized arrhythmia, prolonged QT interval, has been detected on 
electrocardiogram in multiple patients (Pena, Franks et al. 2012). This abnormality is associated 
with syncope and sudden death (Jameson and Walter 2008). 
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Other long-term complications of PA involve the central nervous system. Metabolic 
crises that occur during early childhood, resulting in the accumulation of toxic metabolites, pose 
damage to the central nervous system (Haberlandt, Canestrini et al. 2009). The neurological 
complications that have been reported in case studies include seizures, basal ganglia 
abnormalities, movement disorders, and brain atrophy. PA patients may suffer from number of 
different types of seizures including: generalized tonic-clonic, absence, atonic, focal, focal with 
generalization, and myoclonic. The age of onset of seizures is typically during early childhood, 
often between 7 days to 4 years of age (Pena, Franks et al. 2012). A study of 17 PA patients done 
by Haberlandt et al. concluded that electroencephalogram (EEG) abnormalities and epileptic 
seizures were found in 50% of patients, however they found no relationship between age of onset 
of PA symptoms or number of metabolic decompensations and the development and frequency 
of seizure episodes (Haberlandt, Canestrini et al. 2009).  
Currently there is limited information regarding the developmental status of patients with 
PA. The developmental outcomes have been reported to range from individuals with reduced IQ 
and delayed cognitive skills to individuals who attend regular school without any additional 
support (Pena, Franks et al. 2012). The study by Grünert et al. in 2013 determined that 
neurologic outcome of PA patients can be quite compromised. The study showed that 
approximately three quarters of the study subjects had mental retardation and that there was a 
negative correlation between the subject’s IQ and the number of metabolic decompensations the 
subject experienced. This was found to be the trend even when excluding the subject’s age as a 
factor (Grünert, Müllerleile et al. 2013). To date, there has been no improvement in the 
neurologic outcomes in PA patients despite the advancements of therapeutic interventions and 
treatment protocols (Grunert, Mullerleile et al. 2012, Sindgikar, Rao et al. 2013).  
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Episodes of acute pancreatitis and recurrent acute pancreatitis have been reported in a 
small number of PA patients. Acute pancreatitis should be suspected in PA patients experiencing 
ongoing abdominal pain (Bultron, Seashore et al. 2008). During episodes of metabolic 
decompensation, neutropenia and thrombocytopenia have been reported. With the reported cases 
of hematologic abnormalities, it is thought that this might contribute to PA patients being at an 
increased risk for infection, however this remains uncertain (Pena, Franks et al. 2012).  
Children with PA have a tendency to be small for age due to malnutrition and protein-
restricted diet. Dysmorphic features that are typically seen in individuals with methylmalonic 
aciduria (MMA) can be seen in individuals with PA. These features include: frontal bossing, a 
widened depressed nasal bridge, epicanthal folds, long philtrum, and an upturned curvature of 
the lips (Burton 1998). Rare complications that can be associated with PA are optic atrophy, 
hearing loss, premature ovarian insufficiency (POI), chronic renal failure, and osteoporosis 
(Williams, Hurley et al. 2009, Lam, Desviat et al. 2011).  
3.1.3 Diagnosis  
A clinical diagnosis of PA is defined based on clinical manifestations and time of presentation. 
Generally, patients phenotypically fall into one of two groups, neonatal-onset and late-onset. A 
majority of individuals present with symptoms during the neonatal period and clinical findings 
can be fairly nonspecific. These features include vomiting, poor feeding, lethargy, and hypotonia 
within the first days of birth. If symptoms progress and are left untreated, seizures, metabolic 
acidosis and/or hyperammonemia, and in some cases coma and death, may occur (Grunert, 
Mullerleile et al. 2012). The clinical findings associated with late-onset PA, which occurs 
anytime after the neonatal period, include: failure to thrive, developmental delay, chronic 
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vomiting, protein intolerance, various neurological symptoms, and cardiomyopathy (Grunert, 
Mullerleile et al. 2012). Children and adults with PA can experience acute decompensation that 
is similar to the symptoms associated with the neonatal presentation. Often this is brought on by 
catabolic stressors such as infection, injury, or surgery. 
Newborn screening (NBS) can identify infants with PA. An acylcarnitine profile 
performed by tandem mass spectrometry (MS/MS) on dried blood spots shows an elevated 
propionylcarnitine (C3) level in affected individuals (Chapman, Gropman et al. 2012). When 
infants are symptomatic before the NBS results are available, often the diagnosis is made due to 
the baby’s clinical presentation. In symptomatic individuals, the testing of urine organic acids 
and plasma amino acids distinguishes PA from other organic acidemias. Elevated 3-
hydroxypropionate and the presence of methylcitrate, tiglylglycine, and propionylglycine in the 
urine and elevated glycine in the blood are characteristic of PA patients (Sindgikar, Rao et al. 
2013). To confirm a diagnosis of PA, PCC enzyme activity can be measured in peripheral blood 
leukocytes or cultured skin fibroblasts or molecular genetic testing can be completed.  
Molecular studies for PA, including gene sequencing and deletion/duplication analysis, 
are currently available for both the PCCA and PCCB genes. The mutation detection rate using 
sequence analysis is approximately 80% in the PCCA gene and 99% in the PCCB gene. Use of 
deletion/duplication analysis, which identifies exonic or whole gene-deletions, increases the 
detection rate by approximately 20% in the PCCA gene; deletions in the PCCB gene have not 
been reported to date. If the mutations are known in a family, then DNA analysis can be 
preformed for prenatal diagnosis. If the mutations are unknown, then prenatal diagnosis of PA 
may be achieved via measurement of enzyme activity in cultured chorionic villi cells or amniotic 
fluid cells (Perez-Cerda, Perez et al. 2004). At present, preimplantation genetic diagnosis (PGD) 
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is a valid reproductive option for couples at risk of transmitting mutations in the PCCA or PCCB 
gene to their children (Alberola, Bautista-Llacer et al. 2011). 
3.1.4 Genotype-Phenotype Correlations 
Compound heterozygosity, either in the PCCA or the PCCB genes, occurs in the majority of 
affected individuals, making genotype-phenotype correlations challenging (Pena, Franks et al. 
2012). In general, null alleles are associated with a severe form of PA due to complete absence 
of enzyme activity, and missense mutations are associated with milder forms of PA, presumably 
due to residual enzyme activity (Desviat, Pérez et al. 2004). Null alleles that have been reported 
in the literature include p.Arg313X and Ser562X in the PCCA gene and p.Gly94X and several 
small deletions/insertions and splicing mutations in the PCCB gene. The reported missense 
mutations are p.Ala138Thr, p.Ile164Thr, and p.Arg288Gly in the PCCA gene and p.Asn536Asp 
in the PCCB gene.  There are exceptions to missense mutation causing mild disease: 3 PCCB 
missense mutations, p.Gly112Asp, p.Arg512Cys, and p.Leu519Pro, are reported to affect 
heterododecamer formation and result in undetectable PCC enzyme activity and therefore are 
associated with a severe form of PA (Muro, Pérez et al. 2001).  
The PCC enzymatic activity resulting from different mutations is often the most useful 
indicator to establish severity and prognosis of the condition. However, establishing correlations 
among the mutations, the measured enzymatic activity and the clinical manifestations of PA is 
complicated by the various methods in which PCC activity can be measured (i.e. fibroblasts, 
leukocytes, and in vitro systems). Direct comparisons are difficult because each method may 
yield differing enzymatic activities (Pena, Franks et al. 2012). Consistency of testing systems is 
important when attempting these correlations. 
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In patients who have PA, PCCB mutations are found more frequently than PCCA 
mutations (Pena, Franks et al. 2012). The most common mutation in the PCCB gene in the 
Caucasian population, c.1218_1231del14ins12, represents 32% of mutant alleles (Tahara, Kraus 
et al. 1993, Perez-Cerda, Merinero et al. 2000). A missense mutation in the PCCB gene, 
c.1606G>A (p.Asn536Asp), is associated with a less severe form of PA and is commonly seen in 
some Amish communities, identified in Lancaster, PA (Desviat, Pérez et al. 2004, Strauss and 
Puffenberger 2009).The most common mutation in the PCCB gene in the Japanese population 
c.1304T>C (p.Y435C), represents 25% of mutant alleles in that group (Tahara, Kraus et al. 
1993). In Japan, this particular mutation is associated with a more mild clinical presentation of 
PA and also has been seen in asymptomatic individuals (Yorifuji, Kawai et al. 2002). 
3.1.5 Management Recommendations 
In January 2011, the Children's National Medical Center in Washington, D.C. assembled a group 
of physicians, investigators, and parents to discuss practice guidelines and medical management 
options for patients with PA (Chapman and Summar 2012). This effort included a rigorous 
review of English-language published materials regarding PA, contribution from experts and 
robust debate of any discrepancies. As a result of this meeting, articles were published outlining 
the acute management, chronic management, and health supervision options for PA patients.  
3.1.5.1 Acute Management  
All patients with PA are susceptible to metabolic crises and must have an emergency protocol in 
place to initiate when they show early signs of metabolic decompensation. The recommendations 
for acute management of patients with PA are categorized using a step-wise approach. The first 
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step involves initial care and the stabilization of the potential critically ill patient. This 
intervention may apply to a patient with a known or suspected diagnosis and may take place in a 
healthcare facility that is not considered a metabolic center. This intervention focuses mainly on 
basic life support and obtaining vital signs, placing intravenous lines, and drawing baseline 
laboratory studies. Equally essential is reversal of catabolism, a major source of metabolic 
toxicity. This entails discontinuation of all sources of protein and provision of a non-protein 
calorie source (IV dextrose with electrolytes). Verification of newborn screening results for 
neonates should also be done (Chapman, Gropman et al. 2012). 
The second step in acute management of the symptomatic PA patient is transport to an 
established metabolic center where more aggressive interventions can take place as needed. If the 
patient did not stabilize with the reversal of catabolism, then he/she would require some level of 
accelerated care. Depending on clinical circumstances, this might involve insulin drip, 
hemodialysis or extracorporeal membrane oxygenation (ECMO) in the hyperammonemic 
patient, delivery of ammonia-lowering medications, and carnitine supplementation, all done with 
careful monitoring. Reintroduction of protein should be done as early as possible to prevent 
protein deficiency from contributing to the decompensation (Chapman, Gropman et al. 2012).  
Once the patient is stabilized, the third step involves preparation for discharge of the 
patient and transition from acute to chronic management, including deceleration of acute 
interventions, establishment of a home regimen, and parental training (Chapman, Gropman et al. 
2012). 
3.1.5.2 Chronic Management  
The needs of PA patients will differ depending on the severity of the condition, thus chronic 
management and treatment protocols should be customized for each affected individual. 
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Therefore, not every individual with PA will need all of the medical treatment and surveillance 
options that were proposed for this patient population. The chronic management 
recommendations that have been established in the literature are centered on nutritional 
assessments and laboratory monitoring, neurology, cardiology, immunology, gastroenterology, 
ophthalmology, ancillary treatment, and liver transplant evaluation. Further information 
regarding the specific practice guidelines is outlined in Table 1 (Sutton, Chapman et al. 2012). 
Table 1. Outline of the Chronic Management and Health Supervision of Individuals with Propionic Acidemia 
Specialty Area Practice Guidelines 
Nutrition 
Recommended nutrition assessments at routine outpatient visits - at least 
every 6 months 
• Albumin, ammonia, plasma amino acids (fasting 3-4 hours), prealbumin 
Optional nutrition assessments to consider: 
• Quantitative acylcarnitine profile 
• Urine methylcitric acid 
• Other general measures of nutrition as needed, based on medical 
history, dietary intake, and growth parameters  
o Such as 25-hydroxyvitamin d, iron, selenium, free fatty acids 
etc. 
Diet history review at each visit and adjustments to be made as needed: 
• Normal growth velocity for weight  
• Normal levels of serum albumin and prealbumin 
• Normal levels of plasma isoleucine, methionine, threonine and 
• Valine 
• Normal to elevated levels of plasma glycine	  
Therapeutic 
Services 
Early initiation of physical, occupational, and speech therapy services, to 
continue throughout childhood 
Neurology 
Management of stroke-like episodes 
• Ensure adequate fluid and caloric intake  
• Symptomatic treatment of focal neurological deficits 
Evaluation for seizures 
• EEG at diagnosis and annually  
• Referral to child neurology if epileptiform activity is detected 
Cardiology 
Evaluation for cardiomyopathy 
• Echocardiogram at diagnosis and annually 
o As needed to evaluate shortness of breath, tachycardia or other 
signs and symptoms of cardiac failure 
Screening for Long OTC and other cardiac conduction defects 
• ECG annually  
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Table 1. Continued 
• 24-hour Holter annually  
• ECG and 24-hour Holter during episodes of syncope, fainting, etc.  
Immunology 
CBC with differential at diagnosis, annually, and as needed  
If neutropenia present, institute infection control precautions (isolation, 
gown and glove, etc.) 
Expectant management with judicious use of colony stimulating factors 
only in cases where neutropenia is not resolving or there is evidence of 
bacterial infection per day 
Gastroenterology 
Evaluation and management of acute pancreatitis 
• Vomiting, anorexia, abdominal pain and unexplained acidosis should 
prompt evaluation for pancreatitis  
o Serum amylase and lipase measurements 
• Episodes of acute pancreatitis in PA should be managed using fluids, 
short-term bowel rest, jejunal feeds, and pain management 
• When necessary, total parenteral nutrition can be used in a safe manner 
Ophthalmology 
Evaluation and management of optic atrophy 
• Yearly examination by an ophthalmologist  
o Determine visual acuity, visual examination of the anterior 
chamber, and dilated evaluation of the fundus 
• Treatment of decreased visual acuity 
Ancillary 
Treatment 
Carnitine supplementation 
• 200–300 mg L-carnitine/kg body weight/day divided 2–3 times 
• For acute hyperammonemia and recurrent metabolic decompensations, 
consider doses on the high end of the range (300mg/kg/day)  
Biotin supplementation 
• May consider biotin 5 mg daily 
• If no reduction in plasma propionylcarnitine discontinue biotin 
Pro-motility agents 
• Daily use of laxative at age/weight-appropriate doses 
Bactericidal therapy 
• Metronidazole 10–20 mg/kg/day divided t.i.d. may be considered in 
individuals refractory to other standard interventions 
Gastrostomy tube/button placement 
• May be considered especially in infants and young children  
Port-a-cath placement 
• May be considered with unreliable peripheral venous access  
Liver 
Transplantation 
In individuals with recurrent episodes of hyperammonemia or acidosis that 
are not adequately controlled with medical therapies, liver transplant may 
be considered 
Referenced from "Chronic management and health supervision of individuals with propionic 
acidemia."(Sutton, Chapman et al. 2012) 
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For the more rare complications that have been seen in patients with PA, additional 
screening options can include evaluations by audiology for hearing loss and gynecological 
evaluations for premature ovarian insufficiency (POI) in older females. Lastly, parents should be 
provided with emergency care information that can accompany the patient at all times. A Medic-
alert system should also be in place.  
3.2 THE INBORN ERRORS OF METABOLISM COLLABORATIVE (IBEMC)  
The Inborn Errors of Metabolism Collaborative (IBEMC) is a group of clinicians and research 
coordinators from a number of metabolic centers across the United States who work together to 
compile clinical information and care needs regarding patients who have one of the conditions 
detected or detectable by NBS (Berry, Jurek  et al. 2010). IBEMC was developed in recognition 
of the need to understand more about the natural history and clinical outcomes for patients with 
an inborn error of metabolism (IBEM) by creating a multi-center database to follow and study 
IBEM patients. This is called the Inborn Errors of Metabolism Information System (IBEM-IS). 
The goal of IBEMC in creating such a database of clinical information was to better understand 
the history and outcomes of IBEM patients that were identified by NBS as compared to those 
who were clinically diagnosed later in life. This collection of information is intended to aid in the 
development of clinical practice guidelines and long-term follow up protocols for this set of rare 
metabolic conditions, as well as contribute to development of effective therapeutics through 
identification of biomarkers and support of clinical trials development. 
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3.2.1 The Inborn Errors of Metabolism Information System (IBEM-IS) 
The Inborn Errors of Metabolism Information System (IBEM-IS) was initiated in January 2007 
and data was collected from IBEM patients and their families using a web-based, secure data 
collection platform, called DocSite (Berry, Jurek  et al. 2010). The participating metabolic 
centers entered subject data into the DocSite platform until January 2013, when data collection 
was transitioned to a new data collection platform, Research Electronic Data Capture (REDCap). 
This change was made to provide data compatibility with the ongoing NIH-funded programs 
through the Newborn Screening Translational Research Network (NBSTRN). The Michigan 
Public Health Institute, the University of Minnesota, and participating clinical centers are funded 
to work together to manage and provide support for the IBEM-IS project (NIH-Michigan Public 
Health Institute HD10-019, Children’s Hospital of Pittsburgh: New York-Mid-Atlantic Regional 
Collaborative funding). 
The metabolic centers that participate in IBEM-IS have IRB-approved protocols that 
allow for obtaining consent from individuals or their representatives that permit collection of 
longitudinal, condition-specific information regarding the patient. The data collection tool was 
designed based on an extensive literature review and the current clinical practices of metabolic 
providers, with input and review from multiple metabolic specialists (Berry, Jurek  et al. 2010). 
The data set developers acknowledge that some aspects of the patients’ clinical care are uniform 
among participating centers and there are aspects that differ. For this reason, the collected data 
incorporates elements that reflect the variability of care at the participating centers.  
With the DocSite data collection platform, there were two different data sets that were 
utilized to collect data from the participating subjects. Intake data sets were collected at the time 
of the patients’ enrollment. Interval data sets were collected at each outpatient metabolic visit 
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including the initial enrollment visit. Information was gathered from the subjects and the general 
data elements recorded in the intake and interval data sets are outlined in Table 2.  
Table 2. List of General Data Elements Entered into DocSite 
Data Set General Data Elements 
Intake 
Demographical information  
Socioeconomic status 
Family history 
Prenatal history  
Neonatal history  
Measurements at birth  
Newborn screening information  
Diagnostic testing information  
Past health history  
Emergency management protocols 
Nutritional information  
Other 
Interval 
Demographical information  
Socioeconomic status 
Measurements at visit 
Past health history  
Emergency management protocols 
Care coordination  
Developmental assessments  
Education services 
Home monitoring  
Laboratory studies  
Imaging studies 
Pharmacotherapy   
Nutritional information  
Other 
 
Currently, the REDCap data collection platform works using branching logic such that 
specific questions will be displayed depending on values entered in previous questions. 
Information is obtained at the subjects’ enrollment and at each follow-up visit at the participating 
center. The amount of information collected in REDCap is greater when compared to the 
information that was collected in DocSite. REDCap also allows for comments to be added at the 
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end of each data section and for specific sections (e.g., pregnancy, dialysis, and transplant) it 
directs the provider to complete an additional form. The general data elements that are collected 
in each data sheet are listed in Table 3.  
Table 3. List of General Data Elements Entered into REDCap 
Data Sheet Data Section  General Data Elements  
Intake 
Intake demographics 
Consent  
Demographic information  
Condition  
Care and other studies 
Education 
Ancestral origin, race and 
ethnicity  
Socioeconomics  
Medical coverage  
Language  
Intake family history Family history  
Intake past health history 
Prenatal history  
Pregnancy  
Neonatal history  
Birth measurements 
Health history  
Dialysis  
Transplants 
Other history  
Prior testing  
Eye exam 
Emergency management 
Intake newborn screening Newborn screening Newborn hearing screen 
Intake initial testing 
Symptoms at initial contact 
Diagnostic testing  
Genetic testing  
Parent laboratory studies  
Visit 
Visit demographics and history  
Consent  
Care and other studies 
Education  
Medical coverage  
Family history  
Visit health history  
Health status  
Sick visits  
Procedures  
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Table 3. Continued 
Pregnancy  
Dialysis  
Transplants  
Other procedures  
Visit findings Visit measurements  
Visit ancillary care 
Care coordination  
Emergency management  
Developmental assessment  
Education  
Visit lab studies 
Biochemical labs  
Chemistry labs 
Hematology labs  
Liver labs  
Renal labs  
Miscellaneous labs 
Visit management and treatment 
pharmacotherapy Pharmacotherapy  
Visit management and treatment nutrition Nutrition  
Additional 
forms 
Pregnancy First – eighth pregnancy  Current pregnancy  
Dialysis First – tenth dialysis treatment  
Transplant First – fifth transplant  
 
Anonymized subject data is available to the researchers from all of the participating 
centers. The use of the data for research is encouraged and participating centers each have 
benchmarks both for patient recruitment and data entry, as well as for submission of proposed 
research projects utilizing the accumulated data. In addition, proposals can be submitted for use 
of the data by both researchers involved in the IBEMC and from researchers not involved in the 
IBEMC. Standard operating procedures have been developed for review of submitted protocols 
and access to the compiled data. Two general types of research projects are thus far being 
developed to integrate use of IBEM-IS data. One type of project involves using the IBEM-IS for 
data mining purposes only. Data mining is the process of finding correlations or patterns among 
variables in a large database. The other type of project involves establishing an IBEM-IS study 
cohort using the subjects who have provided informed consent for recontact, followed by 
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recruitment among this cohort of patients for collection of additional relevant data (Berry, Jurek  
et al. 2010). 
As of March 1, 2014, there are 24 centers across the United States with IRB approval to 
enroll patients in IBEM-IS (Appendix A). Over 1,500 subjects have been consented to 
participate and have their long-term progress documented. There are 43 metabolic conditions 
being followed (Appendix B) and currently 46 PA patients have been consented to participate in 
IBEM-IS. 
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4.0  MATERIALS AND METHODS 
The study was designed as a combined analysis of IBEM-IS data and comparison to information 
obtained though telephone interviews of parents and/or guardians of individuals affected by PA. 
The research protocol was submitted to the University of Pittsburgh’s Institutional Review Board 
(IRB) and was approved by expedited review procedure authorized under 45 CFR 46.110 
(Appendix C). The University of Pittsburgh Medical Center (UPMC) has guidelines to ensure the 
confidentiality of electronic protected health information when acquired from UPMC for 
purposes of research under a protocol approved by a nationally accredited IRB. Therefore, to 
comply with these guidelines, the Center for Assistance in Research using eRecord (CARe) was 
contacted to request permission to access the Children’s Hospital of Pittsburgh’s eRecord and 
approval was obtained.  
A proposal for this project was submitted to the IBEM-IS Research Proposal Review 
Team and was reviewed by a 5-member committee and brought to the entire Collaborative for 
final approval. Upon approval by IBEMC, access was granted to a list of data elements, which 
was requested for PA patient data collected from January 1, 2007 to January 1, 2014 (Appendix 
D).  
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4.1 RECRUITMENT PROCEDURES  
A letter was sent to all IBEM-IS site coordinators outside of our institution, asking them to 
contact the parents/guardians of IBEM-IS-consented propionic acidemia patients who are 0-18 
years of age, and who agreed to be re-contacted (Appendix E). The site coordinators were 
provided with the patient invitation letter and a template to use as a cover invitation letter to send 
to their patients (Appendix F and Appendix G). The site coordinators were asked to report to the 
UMPC IBEMC investigators with the number of participants that met inclusion criteria and the 
number of participants contacted regarding the study. If this report did not occur within two 
weeks, the site coordinators were recontacted to obtain this information. This continued every 
two weeks until a response was obtained. Per the patient invitation letter, if the child’s 
parent/guardian expressed willingness to participate, they were instructed to contact the 
investigator to proceed with the study.  
With approval by the CARe team at UPMC, the study team was able to obtain contact 
information using the clinical application, Cerner, for patients with propionic acidemia who are 
0-18 years of age, already consented to the IBEM-IS protocol, who have agreed to be re-
contacted as part of IBEM-IS, and who were seen at Children’s Hospital of Pittsburgh of UPMC 
metabolic clinic. Two subjects were recruited via direct mailing of the invitation letter from the 
local PI and site coordinator (Appendix H). If the child’s parent/guardian did not contact the 
study team within 2-3 weeks after receiving the invitation letter, then a follow-up call was made 
to assess his/her willingness regarding study participation. 
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4.2 INFORMED CONSENT  
A script was designed to obtain consent of the child’s parent/guardian over the phone. The verbal 
“Yes” or “No” to participate in the interview from the parent/guardian was to be documented 
(Appendix I). Review of components of the consent was to occur after contacting the 
parent/guardian via telephone. An overview of the study was to be presented to the parent by the 
investigator; including a description of the focus of the study on assessment of services and 
schooling received by the patient, anticipated questions about perceived unmet needs, and the 
questionnaire/survey nature of the study. Parents/guardians were to be informed that their 
participation is completely voluntary and that the decision to enroll or not to enroll would not 
impact the clinical care of their child at UMPC facilities. There was no compensation for this 
study. The parent/guardian was to be provided with as much time as needed to make the decision 
whether or not to participate in the study and the PI or co-investigator would address any 
questions or concerns they may have. Consent was only to be obtained by a listed investigator on 
the IRB application.  
4.3 TELEPHONE INTERVIEW  
Once the child’s parent/guardian granted permission to be interviewed, the total duration of 
participation was expected to be within one telephone call and would last a minimum of 45 
minutes. Interviews were to be audio recorded for transcription. Identifying information, such as 
the subject’s name, was to be removed from the transcript. A telephone-conducted interview was 
preferred over a paper-based or computer survey to allow the respondents to elaborate on their 
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answers and to enable the interviewer to build rapport and more thoroughly explore responses to 
service utilization practices and unmet needs.  
The investigator was to conduct the telephone interviews within the Medical Genetics 
office suite located at Children’s Hospital of Pittsburgh of UPMC. The interview was to be 
guided by a list of questions regarding which healthcare services used by PA patients. This 
includes which healthcare providers they may be seeing, if they or their family members 
participate in or seek help from various resources and/or support groups, their experience in 
school and early intervention programs, the size of their family including the number of affected 
children, and level of education completed for both parents/guardians, in addition to other 
demographic factors (Appendix J). 
4.4 TELEPHONE INTERVIEW DATA 
The subjects were to be given a study subject number. Research information was to be stored by 
subject number in a password-protected file. Only individuals directly involved in the research 
study were to have access to the protected health information of the patients. Any paper research 
information (such as telephone interview documents) was to be kept in the locked Medical 
Genetics office suite, which is accessible only by swiping a badge. 
The expectation was to enroll subjects and perform the data analysis in the time frame of 
one year. The total number of subjects to be enrolled into this research study at this site was 
estimated to be 25. This number is based on the 46 currently active PA patients that are being 
longitudinally followed in the IBEM-IS protocol. Based on the time available and the estimated 
likelihood that patients would participate, the plan was to interview up to 25 parent/guardians of 
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patients with PA. The data collected from the phone survey was to be compared to the aggregate 
data from the existing IBEM-IS databases. The results of this study were to be used solely for 
descriptive analysis. It is acknowledged that the study population is small and thus would not 
reach statistical power. This is typical of similar studies done with rare disease patient 
populations. 
4.5 IBEM-IS DATA  
A list of specific data variables from the DocSite data set was requested by this investigator and 
submitted to IBEMC for extraction in November 2013. The data elements were examined for 
content. Upon review of the extracted data, a modified research proposal was submitted to 
encompass the REDCap data set and the additional data variables contained within it. The 
REDCap data was extracted in February 2014 and a dataset with the combined data variables 
from DocSite and REDCap was provided to the investigators at UPMC at the end of February 
2014. The data elements from the combined datasets were assessed for quality and content. 
Descriptive statistics were performed using Microsoft Excel. For certain parts of the analysis, 
missing and/or unknown data fields were excluded. IBM’s SPSS Statistics version 21 software 
package was used for analysis on the remaining data variables. 
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5.0  RESULTS 
5.1 DESCRIPTION OF THE PA SUBJECT DATA IN IBEM-IS 
There are 46 patients with PA enrolled in IBEM-IS. From June 2007 to December 2013 there 
have been a total of 137 visits entered into the database. Data was collected from IBEM-IS-
consented patients at their routine metabolic visits at their participating center. The patients did 
not necessarily return for clinic visits on an annual or semi-annual basis to have data collected, 
but rather returned as needed or as prescribed by their health care providers. Over the 6 years, 
some subjects have been lost to follow-up and new subjects have been enrolled.   
5.1.1 Demographical Information 
A little over half of the subjects are male (24/46) and just less than half are female (22/46) 
IBEM-IS. A majority of the patients were 0-5 years of age (30%), with the second most frequent 
group being 11-15 years of age (24%) at intake. The proportion of subjects in other age groups 
are as follows: 11% were 6-10 years of age, 11% were 16-20 years of age, 11% were 21-30 years 
of age, 7% were 31-40 years of age and 4% were 41-50 years of age. One (2%) of the subjects 
did not have an age reported and/or documented at intake (Table 4, Figure 1).  
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Table 4. Percent of Subjects in Each Age Group Reported at Intake 
 
 
 
 
 
 
 
Figure 1. Age of Subjects at Intake 
In 2007, three PA patients were enrolled in IBEM-IS. In subsequent years, three PA 
patients were enrolled in 2008, eight were enrolled in 2009, four were enrolled in 2010, nine 
were enrolled in 2011, ten were enrolled in 2012, and six were enrolled in 2013. The patients’ 
ages at the time of intake are variable within each year and ranges from 0-50 years of age overall 
(Figure 2).  
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Age of Subjects at Intake 
Age  Number of Subjects Percent 
0-5 years 14 30% 
6-10 years 5 11% 
11-15 years 11 24% 
16-20 years 5 11% 
21-30 years 5 11% 
31-40 years 3 7% 
41-50 years 2 4% 
Unknown 1 2% 
 
Total: 46 
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Figure 2. Median Age of Subjects at Intake for Each Year of Enrollment 
Seventy-four percent of the subjects were reported to be Caucasian, 9% were not 
specified, 7% were Hispanic or Latino, 6% were biracial or multiracial, 2% were African 
American, and 2% were classified as other (Figure 3). Ethnicity of each patient was also 
recorded and is illustrated in Figure 4. Of note, 5 subjects were reported to belong to the Amish 
community. Ethnicity was not further specified for 20 Caucasian individuals. Twelve subjects 
were reported to have a European background, one subject is Arabic, and no Asian PA subjects 
were enrolled (Figure 4). 
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Figure 3. Reported Race 
 
Figure 4. Reported Ethnicity 
Almost half (22/46) of the data concerning maternal and paternal education status is 
missing or unknown in the dataset. For those with education status reported, a majority of the 
subjects’ parents completed some level of a college degree. For 5 subjects, the highest level of 
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parental education was reported as 1-8 years; all 5 reported to belong to the Amish community 
(Figure 5).  
 
Figure 5. Reported Maternal and Paternal Highest Level of Education 
Due to the small sample size, a Fisher’s exact test was performed to evaluate the 
likelihood that the reported parent’s level of education and the number of services a child utilizes 
are independent variables. The null hypothesis was that the variables are independent, while the 
alternative was that there is a correlation between parental level of education and number of 
services reported to be utilized (i.e. the higher the level of education the greater number of 
services reported). This test did not find statistical significance (p-value = 0.321)  (Appendix K, 
Tables 18 and 19).   
Fifty-six percent of the data concerning current insurance status is missing and/or 
unknown. The remaining data is almost equally distributed among commercial/private insurance 
(19%) and State/Federal insurance (17%). Medicaid used in addition to another type of insurance 
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was reported in 6% of subjects. One subject reported using the State Children with Special 
Health Needs (CSHN) Program (Figure 6).   
 
Figure 6. Current Insurance Status 
A Fisher’s exact test was performed to evaluate the likelihood that the type of insurance 
and the number of services a child utilizes are independent variables. The null hypothesis was 
that the variables are independent, while the alternative was that there is a correlation between 
type of insurance and number of services reported to be utilized (i.e. commercial/private 
insurance the greater number of services reported). This test did not find statistical significance 
(p-value = 1.000) (Appendix K, Tables 20 and 21).   
5.1.2 Method of Diagnosis in PA Subjects  
Forty-one percent of subjects were diagnosed with PA due to their clinical presentation and 35% 
of subjects were diagnosed by NBS. Other patients were brought to attention because of a sibling 
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with the same condition (11%) or the subjects had missing and/or unknown data (7%). Three of 
the subjects were documented in IBEM-IS has having more than one method of initial diagnosis 
(4% were diagnosed via abnormal NBS and clinical presentation and 2% were diagnosed clinical 
presentation and sibling of a patient with PA). It is unknown if the methods were concurrent at 
initial diagnosis. For this reason, those subjects were differentiated and placed in their own 
category (Table 5). 
 Table 5. Method of Initial Diagnosis in Subjects  
Initial Diagnosis of this IBEM found by: Number of Subjects Percent 
Abnormal NBS 16 35% 
Abnormal NBS and Clinical Presentation 2 4% 
Clinical Presentation  19 41% 
Clinical Presentation and Sibling of Patient with PA 1 2% 
Missing/Unknown Data 3 7% 
Sibling of Patient with PA 5 11% 
 
Total: 46  
 
The subjects were excluded that had either missing or unknown data for the initial 
diagnosis and missing data for the number of days from birth to initiation of intervention and/or 
at time of initial face-to-face metabolic consultation. It was found that in the remaining 33 
subjects, the median number of days of age from birth to initiation of intervention for PA 
diagnosed via abnormal NBS, clinical presentation, and sibling with PA was 9, 180, and 10 
respectively. The maximum number of days of age from birth to initiation of intervention for PA 
diagnosed via abnormal NBS, clinical presentation, and sibling with PA was 2 years 11 months, 
4 years 2 months, and 8 years respectively (Table 6). 
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Table 6. Method of Diagnosis and Median Days of Age from Birth to Initiation of Intervention for PA 
Initial Diagnosis of this 
IBEM Found by: 
Number 
of 
Subjects 
Median Days of Age From 
Birth to Initiation of 
Intervention for PA 
Minimum Maximum 
Abnormal NBS 10 9 3 1065 
Clinical Presentation  18 180 3 1528 
Sibling of Patient with PA 5 10 2 2920 
 
The Wilcoxon rank-sum test was used as a nonparametric alternative to the two-sample t-
test to compare the number of days of age from birth to initiation of intervention for subjects 
diagnosed via abnormal NBS and subjects diagnosed via clinical presentation. The null 
hypothesis was that there is no difference in the number of days of age from birth to initiation of 
intervention for subjects diagnosed via abnormal NBS and subjects diagnosed via clinical 
presentation. While the subjects diagnosed via clinical presentation ranked higher for the number 
of days than the subjects diagnosed via abnormal NBS, this test did not find statistical 
significance (p-value = 0.156) (Appendix L, Tables 22 and 23).   
The median number of days of age at time of initial face-to-face metabolic consultation 
for PA diagnosed via abnormal NBS, clinical presentation, and sibling with PA was 12, 180, and 
20 respectively. The maximum number of days at time of initial face-to-face metabolic 
consultation for PA diagnosed via abnormal NBS, clinical presentation, and sibling with PA was 
2 years 11 months, 4 years 3 months, and 8 years 3 months respectively (Table 7). 
Table 7. Method of Diagnosis and Median Days at Time of Initial Face-to-Face Metabolic Consultation  
Initial Diagnosis of this 
IBEM Found by: 
Number 
of 
Subjects 
Median Days at Time of 
Initial Face-to-face 
Metabolic Consultation 
Minimum Maximum 
Abnormal NBS 10 12 4 1065 
Clinical Presentation  18 180 3 1552 
Sibling of Patient with PA 5 20 1 3030 
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The Wilcoxon rank-sum test was used to compare the number of days of age at time of 
initial face-to-face metabolic consultation for subjects diagnosed via abnormal NBS and subjects 
diagnosed via clinical presentation. The null hypothesis was that there is no difference in the 
number of days of age at time of initial face-to-face metabolic consultation for subjects 
diagnosed via abnormal NBS and subjects diagnosed via clinical presentation. While the subjects 
diagnosed via clinical presentation ranked higher for the number of days than the subjects 
diagnosed via abnormal NBS, this test did not find statistical significance (p-value = 0.239)  
(Appendix L, Tables 24 and 25).  Similar analyses were not done looking at the group of subjects 
with a sibling with PA because of small sample size (n=5).  
For each of the 33 subjects, the number of the days at time of initial face-to-face 
metabolic consultation was subtracted from the number of days from birth to initiation of 
intervention and the absolute value was tallied. This was done to determine whether the two 
numbers differed for each subject, and to help elicit the meaning of “intervention” in this dataset. 
For the majority of the subjects (24/33), the day of intervention was the same day as the time of 
initial face-to-face metabolic consultation. The remaining 9 subjects had differences reported 
between the two days. Six subjects reported a difference of less than 2 weeks: one subject 
differed by 1 day, two subjects differed by 7 days, two subjects differed by10 days, and one 
subject differed by 12 days. Three subjects reported a much greater difference in days between 
intervention and metabolic consultation: one subject differed by 24 days, one subject differed by 
50 days, and one subject differed by 110 days (Figure 7).  
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Figure 7. Difference in the Number of Days Between First Intervention and Metabolic Consultation 
To assess the timing of intervention in the 33 subjects, the number of the days at time of 
initial face-to-face metabolic consultation was subtracted from the number of days from birth to 
initiation of intervention. The majority of subjects (73%) had the initiation of intervention occur 
on the same day as their first face-to-face metabolic consultation. Negative numbers 
corresponded with the initiation of intervention for PA occurring “before” the first face-to-face 
metabolic consultation took place, this was seen in 15% of the subjects. Positive numbers 
corresponded with the initiation of intervention for PA occurring “after” the first face-to-face 
metabolic consultation took place, this was seen in 12% of the subjects (Figure 8).   
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Figure 8. Timing of Intervention and Face-to-face Metabolic Consultation 
5.1.3 Mutation Status and Genetic Counseling of PA Subjects 
Genotype information was available on 17 subjects. Seventy-one percent (12/17) of the subjects 
had mutations in the PCCB gene. Of the 10 possible alleles for PCCA, 3 could not be identified, 
and 4 had not been previously described in the literature. Of the 24 possible alleles PCCB, 7 had 
not been previously described in the literature. Complete genotype information was available for 
6 subjects (one subject with PCCA gene mutations and 5 subjects with PCCB gene mutations). A 
majority (4/6) of these subjects were compound heterozygotes. Two subjects (subjects 25 and 
28) were homozygous for the missense N536D allele in the PCCB gene that has been identified 
in the Amish community in Lancaster, PA and associated with a milder phenotype. These 
subjects also reported being Amish as their ethnicity. One subject (subject 13) was a compound 
heterozygote for a nonsense and a missense mutation in the PCCB gene, one subject (subject 16) 
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was a compound heterozygote for an exon skipping and a frameshift mutation in the PCCA gene, 
and two subjects (subjects 14 and 29) were compound heterozygotes for different missense and 
frameshift mutations in the PCCB gene. Reported mutations were found in the current published 
literature, The Human Gene Mutation Database (HGMD), as well as database for PCCA and 
PCCB gene mutations, maintained by Jan Kraus, PhD at http://cbs.lf1.cuni.cz/pcc/pccmain.htm 
(last accessed on March 25, 2014) (Table 8 and Table 9). 
Table 8. Subjects Documented with Mutations in the PCCA gene  
Patient 
ID Allele 1 
Allele 1: Mutation 
Description Allele 2 
Allele 2: Mutation 
Description 
10 c.1023dupT --- Deletion exon 3-4 
Large genomic deletiona 
(Desviat, Sanchez-Alcudia 
et al. 2009) 
16 c.782A>G p.E261G 
Exon 17 skippingb 
(Desviat, Clavero et al. 2006) 
c.923dupT 
p. L308fs 
Insertion/deletion resulting 
in a frameshift mutation 
and stop codon 
(Desviat, Pérez et al. 2004) 
19 c.1591T>C --- Not Identified --- 
20 c.1591T>C --- Not Identified --- 
40 
c.231+47_50delTATT 
variant of unknown 
significance in intron 3 
--- Not Identified --- 
a
Expression analysis in a eukaryotic system was performed for the deletion involving exons 3–4 involving 39 amino 
acids. The results demonstrated a total absence of residual activity of the protein, confirming its pathogenicity 
(Desviat, Sanchez-Alcudia et al. 2009). 
 
b
Novel mutation reported in the literature 
 
 
---Mutation has not been previously reported in the literature  
 
 
 
 
 
 
 39 
Table 9. Subjects Documented with Mutations in the PCCB gene 
Patient 
ID Allele 1 
Allele 1: Mutation 
Description Allele 2 
Allele 2: Mutation 
Description 
11 c.483C>T --- c.683C>T p.P228L 
Missense mutation 
(Desviat, Pérez et al. 2004) 
13 c.331C>T p.R111X 
Nonsense mutation 
(Sanchez-Alcudia, Perez et al. 
2012) 
c.1606A>G 
p. N536D 
Missense mutationa 
(Desviat, Pérez et al. 2004)  
14 c.1218del14ins12 p.E407fs 
Insertion/deletion resulting in 
a frameshift mutation and 
stop codonb 
(Desviat, Pérez et al. 2004) 
c.683C>T 
p.P228L 
Missense mutation 
(Desviat, Pérez et al. 2004) 
25 c.1606A>G p. N536D 
Missense mutationa 
(Desviat, Pérez et al. 2004) 
c.1606A>G 
p. N536D 
Missense mutationa 
(Desviat, Pérez et al. 2004)  
28 c.1606A>G p. N536D 
Missense mutationa 
(Desviat, Pérez et al. 2004)  
c.1606A>G 
p. N536D 
Missense mutationa 
(Desviat, Pérez et al. 2004)  
29 c.335G>A p. G112D 
Missense mutationc 
(Desviat, Pérez et al. 2004) 
c. 1204delG 
p. A402fs 
Insertion/deletion resulting 
in a frameshift mutation 
and stop codon 
(Desviat, Pérez et al. 2004) 
31 c.683C>T p.P228L 
Missense mutation 
(Desviat, Pérez et al. 2004) IVS13+1G>C --- 
32 c.683C>T p.P228L 
Missense mutation 
(Desviat, Pérez et al. 2004) IVS13+1G>C --- 
35 c.398T>C --- c.415C>T p.Q139X 
Nonsense mutation 
http://cbs.lf1.cuni.cz/pcc/p
ccmain.htm 
36 c.386-387delTTinsAAC --- 
c.1218del14ins12 
p.E407fs 
Insertion/deletion resulting 
in a frameshift mutation 
and stop codon b 
(Desviat, Pérez et al. 2004) 
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Deletion of 
GGGCATCATCCGGC 
at bases c.1218_1231 
--- c.1495C>T p.R499X 
Nonsense mutation 
(Desviat, Pérez et al. 2004) 
44 c.1398+2delT --- c.1606A>G p. N536D 
Missense mutationa 
(Desviat, Pérez et al. 2004) 
a
Associated with a less severe form of PA. Seen in some Amish communities, identified in Lancaster, PA (Desviat, 
Pérez et al. 2004, Strauss and Puffenberger 2009) 
 
b
Most frequent mutant allele reported in individuals of northern European origin (Tahara, Kraus et al. 1993, Perez-
Cerda, Merinero et al. 2000). 
 
c
Affects heterododecamer formation and is associated with undetectable PCC enzyme activity and the severe 
phenotype (Muro, Pérez et al. 2001) 
 
---Mutation has not been previously reported in the literature  
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The clinical information documented in IBEM-IS for the 6 subjects with complete 
genotype information is listed in Table 10. Out of all the variables requested, the only variables 
with documented information was age, ethnicity, number of hospitalizations prior to intake in 
IBEM-IS, number of days of age from birth to initiation of intervention for PA, the method of 
initial diagnosis by which the IBEM was found, and echocardiogram results obtained prior to 
intake in IBEM-IS. None of the subjects reported any other health care services received 
currently or community resources currently received. Only one subject, Subject 13, reported a 
list of providers seen at the metabolic visit, which included a physician, dietician, genetic 
counselor, and nurse. None of the subjects reported having any birth defects or comorbidities, 
with the exception being Subject 28, who was reported to have asthma.  
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Table 10. Subjects with Complete Genotype and the Clinical Information Documented in IBEM-IS 
Patient 
ID Gene Allele 
Classification 
Based on 
Literature 
Age at 
Intake 
(years) 
Ethnicity 
Number of 
Hospitalizations 
Prior to Intake 
in IBEM-IS 
Days of Age:  Initial 
Diagnosis 
of this 
IBEM 
Found by: 
Echocardiogram 
Results Obtained 
Prior to Intake in 
IBEM-IS 
Birth to 
Initiation of 
Intervention  
Initial Face 
to Face 
Metabolic 
Consultation 
13 PCCB p.R111X Severe 3 European 0 Unknown Unknown Abnormal NBS N/A p.N536D Mild 
14 PCCB p.P228L Mild  36 Not Specified 5 1528 1552 
Clinical 
Presentation Normal p.E407fs Severe 
16 PCCA p.E261G Novel 2 Not Specified 2 Unknown 134 
Abnormal 
NBS Normal p.L308fs Severe 
25 PCCB p.N536D Mild  12 Amish Unknown 150 150 Abnormal NBS N/A p.N536D Mild 
28 PCCB 
p.N536D Mild 
18 Amish 0 27 20 
Sibling of 
Patient with 
PA 
Normal p.N536D Mild 
29 PCCB p.G112D Severe 15 European 10 3 3 Clinical Presentation Normal  p.A402fs Severe 
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Ninety-six percent (44/46) of the PA subjects in IBEM-IS reported having genetic 
counseling for their condition. For one subject, the data for this variable was missing and/or 
unknown and one subject reported that genetic counseling was not provided (Figure 9).  
 
Figure 9. Was Genetic Counseling for this Disorder Provided? 
5.1.4 Analysis of Service Utilization Data 
Intake/consent visits for each subject were isolated and assessed for service utilization data 
content. The data variables of interest are the reported “other health care services received 
currently”, the “community resources received currently”, and “providers seen at this metabolic 
visit”. This set of data (Table 11) incorporates the 28 subjects with only one visit documented in 
IBEM-IS and the first visit of the 18 subjects with multiple (2 or more) visits documented in the 
database. A majority (67-76%) of the desired data was missing or unknown.  
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Table 11. Content of the IBEM-IS Data at Intake  
 Number of Subjects with 
Reported/Documented Data Percent 
Number of Subjects with 
Missing/Unknown Data Percent 
Other Heath Services 
Received Currently 14 30% 32 70% 
Community Resources 
Received Currently 11 24% 35 76% 
Providers Seen at this 
Metabolic Visit 15 33% 31 67% 
 
There are 18 subjects with more than one visit documented in IBEM-IS. These subjects 
and subsequent visits were isolated to assess for service utilization data content. The data 
variables of interest are the reported “other health care services received currently”, the 
“community resources received currently”, and “providers seen at this metabolic visit”. This set 
of data (Table 12) incorporates 18 subjects with a total of 106 follow-up visits documented in the 
database. The number of visits entered in IBEM-IS for each subject ranges from 2 to 18. A 
majority (83-89%) of the health services and provider data was reported and/or documented. 
Approximately half (46%) of the community resources data was missing or unknown. 
Table 12. Content of the IBEM-IS Data for “Follow-up” Subjects  
 Number of Visits with 
Reported/Documented Data Percent 
Number of Visits with 
Missing/Unknown Data Percent 
Other Heath Services 
Received Currently 88 83% 18 17% 
Community Resources 
Received Currently 57 54% 49 46% 
Providers Seen at this 
Metabolic Visit 94 89% 12 11% 
 
All of the visits with missing or unknown data for the follow-up subjects were excluded 
and the only remaining variables with reported and/or completed data were analyzed. The 
percent of each heath service was calculated by dividing the number of times the particular 
health service was reported by the total number of health service reports. The health services that 
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were reported the most were cardiology (21%), occupational therapy (13%), physical therapy 
(12%), neurology (11%), speech-language therapy (8%), and ophthalmology (8%). All of the 
other health services were reported with a rate equal to or less than 5% (Table 13).   
Table 13. Health Services Reported by PA Subjects in IBEM-IS 
Other Health Services Received Currently Number of Times Reported Percent 
Audiology 3 1% 
Behavioral/Developmental Pediatrics 1 0.36% 
Cardiology 59 21% 
Dentistry 7 3% 
Dietitian 11 4% 
Feeding Therapy 1 0.36% 
Gastroenterology 5 2% 
Hematology 2 1% 
Home Health Care 1 0.36% 
Nephrology 3 1% 
Neurology 30 11% 
None 14 5% 
Occupational Therapy 37 13% 
Ophthalmology 21 8% 
Orthopedics 7 3% 
Other 4 1% 
Physical Therapy 34 12% 
Preschool 2 1% 
Primary Care Provider 4 1% 
Pulmonology 6 2% 
Speech-Language Therapy 22 8% 
Surgery 1 0.36% 
Urology 1 0.36% 
 
Total: 276 
  
The percent of each community resource was calculated by dividing the number of times 
the particular community resource was reported by the total number of community resource 
reports. For community resources received currently, “none” (41%) and “other” (8%) were 
reported a majority of the time. The community resources that were reported the most were 
preschool (11%), social services – developmental disability (11%), social services – medical 
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(8%), and daycare (7%). All of the other community resources were reported with a percent 
equal to or less than 5% (Table 14). 
Table 14. Community Resources Reported by PA Subjects in IBEM-IS 
Community Resources Received Currently  Number of Times Reported Percent 
Daycare 5 7% 
Family Support Group Related to this IBEM 2 3% 
Family Support - Other 2 3% 
Head Start 2 3% 
None 31 41% 
Nutritional Services (WIC/MAC) 4 5% 
Other 6 8% 
Preschool 8 11% 
Social Services - County 2 3% 
Social Services - Developmental Disability 8 11% 
Social Services - Medical 6 8% 
 
Total: 76 
    
The percent utilization for each provider was calculated by dividing the number of times 
the particular provider was reported by the total number of provider reports. All 18 subjects 
reported seeing a physician and dietitian. The amount of times these providers were reported is 
comparable between the two (37% for dietitian and 36% for physician). The other providers 
were reported to be utilized less in comparison with a rate equal to or less than 7% (Table 15).  
Table 15. Providers Reported by PA Subjects in IBEM-IS 
Providers Seen at this Visit Number of Times Reported Percent 
Dietitian 89 37% 
Genetic Counselor 17 7% 
Nurse 13 5% 
Nurse Practitioner 12 5% 
Physician 87 36% 
Social Worker 10 4% 
 
Total: 228 
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Variability has been observed in the number of times subjects reported utilizing a 
particular service, resource, and/or provider. Across the different services that were reported, 
some subjects reported utilizing the service once and other subjects reported using the same 
service multiple times. The tables in Appendix M-O reflect this observation in the follow-up visit 
data. For instance, 12 subjects reported receiving services from cardiology and cardiology has 
been reported 59 times. However, each subject did not utilize this services equally: 4 subjects 
reported twice, 2 subjects reported three times, 1 subject reported four times, 2 subjects reported 
five times, 1 subject reported nine times, 1 subject reported ten times, and 1 subject reported 12 
times.  
To assess the number of times services were reported per year, as some subjects were in 
IBEM-IS for longer periods of time than others and may report using more services, the data was 
reorganized. From the original 46 subjects and 137 visits that were entered in IBEM-IS, all of the 
visits with missing and/or unknown data were eliminated. This resulted in a sample size of 23 
subjects with a total of 93 visits. The six services that were observed to be reported the most 
were cardiology, occupational therapy, physical therapy, neurology, speech-language therapy, 
ophthalmology, and none. There was no health service utilization data for years 2007 and 2008. 
In years 2009-2013, the most services were reported in 2012 and the least services were reported 
in 2009. The sample size for each year was determined by the total number of subjects 
participating in IBEM-IS that year and does not reflect the number of newly enrolled subjects per 
year (Figure 10).  
 47 
 
Figure 10. Health Services Reported by Subjects Per Year  
The number of subjects enrolled each year was determined. The total number of subjects 
is considered to be 44 because 2 subjects did not have an intake visit included in the data 
provided to the investigator. The number of newly enrolled subjects was then compared to the 
total number of visits that were entered into IBEM-IS to infer what proportion of the data is 
attributed to newly enrolled subjects, as they have less time to be followed in IBEM-IS and 
therefore may have fewer opportunities to report using services (Table 16).  
Table 16. Proportion of New Subject Data Entered Per Year  
 
2007 2008 2009 2010 2011 2012 2013 Total 
Number of Newly Enrolled Subjects 3 3 8 5 9 10 6 44 
Total Number of Visits Entered 3 3 17 18 26 43 27 137 
Proportion of New Subject Data Entered 1.00 1.00 0.47 0.28 0.35 0.23 0.22 0.32 
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5.2 IDENTIFICATION OF CURRENT SERVICE UTILIZATION 
Current service utilization in PA patients was not identified because of the inability to recruit 
subjects to interview for the study. At the investigator’s site, the Children’s Hospital of 
Pittsburgh of UMPC, two out of the total three PA patients being followed at the institution fit 
the inclusion criteria for the study. The parents of both patients were sent invitation letters in the 
mail directly from the investigator. Two weeks after the letters were mailed, the patients were 
called via telephone to inquire about participation. After leaving voicemail messages, contact 
was made with the parents of both patients and reasons for lack of response were communicated 
to this investigator. One patient’s family had recently moved and had not received the letter as of 
the time of the call and the mother asked to call the investigator when she had more time. The 
other patient’s father was out of town for the previous two weeks and did not know about the 
study.  The family then moved to a different state and follow-up was lost. In the end, both 
parents did not return the investigators call to participate in the telephone interview.  
To recruit PA subjects from the other 26 sites participating in IBEM-IS, an e-mail was 
sent to each of the co-investigators and research coordinators using a contact list that was 
provided by IBEMC. The e-mail contained an introduction to the study, an explanation of 
IBEMC’s approval, an attached letter explaining the coordinators’ role in the study, an attached 
letter of invitation for the parents/guardians of patients that meet inclusion criteria, a request to 
send the invitation letter in a timely manner, an attached cover letter for their convenience, and a 
request to reply back with the number of patients to whom the invitation letter was sent. The 
responses from each site (de-identified) are listed in Table 17. 
After the first e-mail, only 4 out of the 26 sites responded (15%). One site only had one 
patient they were following and the letter was sent in the mail. Another site reported that all of 
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their PA patients were over 18 years of age. Two sites stated that they were no longer 
participating in IBEMC.  
A second e-mail was sent to the 22 sites that did not respond, two weeks after the initial 
correspondence, as a reminder. Seven more sites responded (42%): one site reported that they 
were not following any PA patients in their clinic, two sites distributed the letter to one patient, 
and one site distributed the letter to 4 patients.  The three other sites stated that their IRB 
required them to write a study addendum in order to send the invitation letter to their patients and 
that they would report back pending their submission. Only one of these sites responded, 
indicated that their IRB did not require an addendum, and reported that the invitation letter was 
sent to 4 PA patients.   
A third point of contact (telephone and/or e-mail) was made, two weeks after the second 
e-mail, by the co-investigator of this study who is also the IBEM-IS site coordinator at the 
Children’s Hospital of Pittsburgh of UPMC. This form of contact was made in attempt to 
facilitate a higher response rate from other IBEM-IS site coordinators. Out of the 9 sites that 
were contacted, 6 did not respond, one sent out 2 invitation letters, one reported that they were 
no longer participating in IBEMC, and one site had 1 PA patient that had not been consented to 
IBEM-IS.  
After three separate attempts were made to contact the 26 sites, only 14 (54%) sites 
responded. Out of the 14 responding sites, only 6 (43%) sites had available PA patients to 
recruit. A total of 13 invitation letters were sent to eligible PA patients.  At the closure of the 
enrollment period on December 31, 2013 none of the invited PA patients called to express 
interest in participation.  
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Table 17. Site Coordinator Response Log 
Site First  E-mail 
Second 
E-mail 
Third 
Contact 
Date 
Responded Response  
Number of 
Patients 
A 10/15/13  ---------- ---------------- 10/15/13 Not currently participating  0 
B 10/15/13 10/29/13 ---------------- 10/30/13 No PA Patients  0 
C 10/15/13 10/29/13 11/13/13  --------------  ---------------------------------  ------------- 
D 10/15/13 10/29/13 11/13/13  --------------  ---------------------------------  ------------- 
E 10/15/13 10/29/13 11/13/13  --------------  ---------------------------------  ------------- 
F 10/15/13 10/29/13 ----------------  --------------  ---------------------------------  ------------- 
G 10/15/13 10/29/13 ----------------  --------------  ---------------------------------  ------------- 
H 10/15/13 10/29/13 ---------------- 10/29/13 IRB addendum approved 4 
I 10/15/13 10/29/13 ---------------- 10/31/13 Invitation letters sent 4 
J 10/15/13  ---------- ---------------- 10/15/13 All PA patients over 18  0 
K 10/15/13  ---------- ---------------- 10/15/13 Invitation letters sent 1 
L 10/15/13 10/29/13 ----------------  --------------  ---------------------------------  ------------- 
M 10/15/13 10/29/13 11/13/13  --------------  ---------------------------------  ------------- 
N 10/15/13 10/29/13 ----------------  --------------  ---------------------------------  ------------- 
O 10/15/13 10/29/13 ----------------  --------------  ---------------------------------  ------------- 
P 10/15/13 10/29/13 ----------------  --------------  ---------------------------------  ------------- 
Q 10/15/13 10/29/13 ---------------- 10/29/13 Pending IRB addendum  ------------- 
R 10/15/13 10/29/13 11/13/13 11/15/13 Not currently participating  0 
S 10/15/13 10/29/13 ---------------- 10/29/13 Pending IRB addendum  ------------- 
T 10/15/13 10/29/13 ---------------- 11/1/13 Invitation letters sent 1 
U 10/15/13  ---------- ---------------- 10/15/13 No longer participating  0 
V 10/15/13 10/29/13 11/13/13  --------------  ---------------------------------  ------------- 
W 10/15/13 10/29/13 ---------------- 11/6/13 Invitation letters sent 1 
X 10/15/13 10/29/13 11/13/13   --------------  ---------------------------------  ------------- 
Y 10/15/13 10/29/13 11/13/13  11/13/13 Invitation letters sent 2 
Z 10/15/13 10/29/13 11/13/13  12/2/13 1 PA patient, not consented 0 
5.3 COMPARISON OF SERVICE UTILIZATION DATA  
With the inability to recruit participants for the study, the interview of parent/guardians of PA 
patients was not done. Without the interview of parents and/or guardians, current service 
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utilization information in PA patients was not assessed. Therefore the parent-stated service 
utilization data could not be compared to the documented aggregate data in IBEM-IS.  
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6.0  DISCUSSION 
6.1 DESCRIPTION OF THE PA SUBJECT DATA IN IBEM-IS 
6.1.1 Demographical Information 
Approximately half of the subjects entered in IBEM-IS were male and half were female. The 
equal distribution of affected males and females is characteristic of the autosomal recessive 
inheritance seen in this condition.  
The majority of subjects fell within 0-20 years of age and a handful of subjects were 21 
years of age and older, with the oldest subject being 50 years of age. The preponderance of 
subjects 0-20 years of age in IBEM-IS may be due to the focus on the pediatric population 
among the participating metabolic centers that are primarily located within pediatric hospitals. 
However, the progress made in the treatment of PA has improved life expectancy and therefore 
more patients are surviving later in life (Dionisi-Vici, Deodato et al. 2006). This may explain the 
upper age range of PA subjects in IBEM-IS.  
PA is a pan-ethnic condition, however it appears to be more common in several 
populations worldwide (Desviat, Pérez et al. 2004). The populations with higher incidences of 
PA are the Inuit population of Greenland, some Amish communities, Saudi Arabians, and the 
Japanese. Very few PA subjects entered in IBEM-IS originated from one of these populations. 
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Five subjects were reported to belong to the Amish community, one subject reported to be 
Arabic, and no Japanese or Greenland Inuit subjects were enrolled. This occurrence may be 
attributable to the area of the Untied States from which subjects were recruited and enrolled. The 
14 states participating in IBEM-IS are as follows: Illinois, Indiana, Kentucky, Michigan, 
Minnesota, Missouri, Nebraska, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, South 
Dakota, and Wisconsin. The participating centers are located in a combination of select states 
from the Region 4 Genetics Collaborative, the Heartland Genetics and Newborn Screening 
Collaborative, and New York-Mid-Atlantic Consortium (NYMAC) for Genetic and Newborn 
Screening services. It is likely that the population of these states from the Midwest and Mid- and 
South-Atlantic do not have significant enough numbers of individuals of Greenlandic, Saudi 
Arabian, and Japanese ancestry to allow for occurrence of this rare disorder in these groups.  
Over half of the data regarding parental highest level of education and current insurance 
status was missing and/or unknown in IBEM-IS, therefore the interpretation of this data is 
limited. A Fisher’s exact test did not determine a correlation between level of parental education 
or type of insurance and the number of health services reported to be utilized and had a lack of 
statistical significance.  
6.1.2 Method of Diagnosis in PA Subjects  
Initial diagnoses of PA can be made by an abnormal NBS, clinical presentation, and/or having a 
sibling with PA. The number of days of age from birth to initiation of intervention for PA and 
days at time of initial face-to-face metabolic consultation were documented for each subject. The 
median number of days to initiation of intervention and days at time of consultation diagnosed 
via abnormal NBS, clinical presentation, and sibling with PA varied. While the subjects 
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diagnosed via clinical presentation appeared to have a higher number of days than the subjects 
diagnosed via abnormal NBS, the Wilcoxon rank-sum test did not find statistical significance 
and therefore a precise interpretation regarding differences between these two groups cannot be 
made.  
The median number of days until intervention and at first consultation was similar in 
patients diagnosed via abnormal NBS and those having a sibling with PA. This may be the case 
for both of these groups of patients because the subjects were brought to medical attention earlier 
in life because of the test results and/or family history and were not yet symptomatic. The 
median number of days until intervention and at first consultation was largest for the patients 
diagnosed by clinical presentation, which reflects the known variability of this condition 
(Grunert, Mullerleile et al. 2012).  
The minimum number of days from birth to initiation of intervention and at first 
consultation for PA is similar among each method of diagnosis: 1-4 days of life. This is 
representative of the prompt identification and diagnosis of PA with newborns that are 
symptomatic within hours or days after birth and those subjects who were brought to attention 
earlier in life due to abnormal newborn screening results and/or family history.  
The maximum number of days of age from birth to initiation of intervention and at first 
consultation for PA was varied for each group. The maximum number of days was the largest for 
a patient with a sibling with PA. This subject may be an outlier for this group and it is possible 
that he or she was only brought to attention because of the family history and still was not 
symptomatic at 8 years of age. Asymptomatic PA, as observed by Wolf et al. (1979) in a 13-
year-old girl, seems to be rare (Wolf, Paulsen et al. 1979, Grunert, Mullerleile et al. 2012). In this 
case, the subject may have been identified through diagnosis of a symptomatic younger sibling. 
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Additionally, a subject from the abnormal NBS group was first brought to attention at 3 years of 
age. This is the only subject that was greater than 45 days of age in this group and it is unclear as 
to the reason for late intervention other than a late onset of symptoms. It may reflect differences 
in how the various centers define “intervention,” as well. 
Due to the possibility that the definition of “intervention” may be different for the various 
healthcare professionals entering data in IBEM-IS, the differences in the number of days from 
birth to initiation of intervention and the number of the days at time of initial face-to-face 
metabolic consultation was determined. To some healthcare professionals, “intervention” may 
mean the time in which the patient first sees a metabolic physician due to the identification of 
PA. To others, “intervention” may mean the time in which the patient receives medical 
treatment, either for screening/prevention of PA symptoms or for clinical symptoms associated 
with PA. In the majority of the cases, the day of intervention was the same day as the time of 
initial face-to-face metabolic consultation. This suggests that initiation of intervention and first 
metabolic consultation are regarded as the same. In the remaining cases that had differences 
reported between the two days, some of them only differed by 1-2 weeks. This observation may 
be attributed to scheduling matters. A possible scenario may be a child presented to the 
emergency room due to metabolic decompensation and received treatment, and then he or she 
was scheduled for an outpatient metabolic visit 1-2 weeks later. In a few cases, the number of 
days differed considerably.  One subject differed by 50 days and one subject differed by 110 
days. The interpretations for these finings are challenging, however the difference in the number 
of days may reflect less severe symptomology not requiring immediate treatment or consultation, 
insurance coverage issues and or other obstacles experienced in obtaining follow-up care. 
Additionally, for cases that had differences reported between the two days, there did not seem to 
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be consistency in the timing of interventions in regard to initial metabolic consultation. 
Nonetheless, the clinical heterogeneity and variable age of onset described in the literature for 
PA patients are evident in range of days until intervention and at first metabolic consultation 
observed in each group (Grunert, Mullerleile et al. 2012, Grünert, Müllerleile et al. 2013).  
6.1.3 Mutation Status PA Subjects 
Limited information regarding genotype information was available for the PA subjects in IBEM-
IS. Only 37% (17/46) of subjects had their mutation status reported. Of the 34 possible alleles in 
these 17 patients, 3 could not be identified and 11 had not been previously described in the 
literature. Seventy-one percent of the subjects had mutations in the PCCB gene. This is 
consistent with what is reported in the literature for PA patients; PCCB mutations are found 
more frequently than PCCA mutations (Pena, Franks et al. 2012). Complete genotype 
information was only available for 13% (6/46) subjects, thus making genotype/phenotype 
correlations challenging.  
The subjects’ mutation status was entered in IBEM-IS without standardized and uniform 
use of nomenclature. Some subjects’ mutations were documented on a DNA level and others 
were documented on a protein level. In some cases, the specific mutation was transcribed from 
the laboratory report in a descriptive format and did not use standard mutation nomenclature. 
Additionally, the gene in which the mutation was found was not clarified for all of the subjects. 
A number of inferences had to be made for the gene. Either the mutation was reported previously 
in the literature in the PCCA or the PCCB gene, or the subject already had one mutation 
identified in one allele of the PCCA or PCCB gene. Given all of these areas of potential error, the 
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classification and interpretation of the PCCA and PCCB mutations for each subject was 
challenging.  
Compound heterozygosity was observed in the majority of the 17 subjects with reported 
mutations (15/17), regardless of whether both mutations had been previously described in the 
literature. Therefore, the determination of phenotypic severity in these subjects is challenging 
because of the different genotype-phenotype correlations associated with each mutation type. In 
general, mutations characterized as null alleles, which comprise mutations predicted by the 
nature of the DNA change (nonsense mutations, out-of-frame deletions and insertions, splicing 
mutations resulting in frameshifts) and those determined experimentally (mutations without 
detectable enzyme activity), are associated with more severe forms of PA. Missense mutations 
retaining partial activity are associated with milder forms of PA (Desviat, Pérez et al. 2004). The 
PCC enzymatic activity resulting from different mutations is often the most useful indicator to 
establish severity and prognosis of the condition (Pena, Franks et al. 2012), however only one 
PA subject in IBEM-IS had his/her enzyme level recorded, thus enzyme activity cannot be 
utilized in this study for correlative purposes. In future studies, the Polymorphism Phenotyping 
v2 (Poly-Phen2) tool may be used to predict the possible impact of an amino acid substitution on 
the structure and function of PCCA and PCCB genes.  
Among the subjects who had complete genotype information, Subject 29 had the PCCB 
missense mutation, G112D. This particular mutation is reported in the literature to affect 
heterododecamer formation and is associated with undetectable PCC enzyme activity and the 
severe phenotype (Muro, Pérez et al. 2001). This subject had a frameshift mutation (A402fs) on 
the second allele (Desviat, Pérez et al. 2004). By having compound heterozygosity 
(G112D/A402fs) for two “severe” or null alleles, this genotype would be associated with a more 
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severe phenotype. Subject 29 was diagnosed via clinical presentation and was 3 days old at 
intervention and first face-to-face contact with a metabolic physician. This subject was enrolled 
in IBEM-IS at 15 years of age and reported 10 hospitalizations and a normal echocardiogram 
prior to intake; other clinical information is missing and/or unknown. While the subject had a 
higher number of hospitalizations prior to intake, they occurred over 15 year time period; 
without knowing more about these episodes, it is difficult to determine whether they correlate 
with clinical severity.  
Subject 13 is a compound heterozygote for nonsense and missense (R111X/N536D) 
mutations in the PCCB gene and Subject 14 is a compound heterozygote for missense and 
frameshift (P228L/E407fs) mutations in the PCCB gene. These subjects would be considered 
functionally hemizygotes, as the “severe” or null allele is combined with a “mild” or missense 
allele (Perez-Cerda, Merinero et al. 2000). Subject 13 was diagnosed via abnormal NBS and did 
not have any hospitalizations prior to intake in IBEM-IS at 3 years of age; other clinical 
information is missing and/or unknown. Therefore genotype/phenotype correlations cannot be 
made in this subject. Subject 14 was diagnosed via clinical presentation and was 4 years and 2 
months old at intervention and 4 years and 3 months old at first face-to-face contact with a 
metabolic physician. This subject was enrolled in IBEM-IS at 36 years of age and reported 5 
hospitalizations and a normal echocardiogram prior to intake; other clinical information is 
missing and/or unknown. Given the limited number of hospitalizations at age 36, it may be 
possible that this subject has less severe symptomology, but supporting data are limited.  
Subject 16 is a compound heterozygote for both exon skipping and frameshift 
(E261G/L308fs) mutations in the PCCA gene. The E261G allele is a novel mutation reported in 
the literature and a specific genotype-phenotype correlation has not been made (Desviat, Clavero 
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et al. 2006). Subject 16 was diagnosed via abnormal NBS, was 34 days of age at first face-to-
face contact with a metabolic physician and had 2 hospitalizations and a normal echocardiogram 
prior to intake in IBEM-IS at 2 years of age; other clinical information is missing and/or 
unknown. Precise genotype/phenotype correlations cannot be made in this subject at this time. 
Only two subjects have homozygous mutations in the PCCB gene. Subject 25 and 
Subject 28 were reported to have 2 copies of the missense, N536D, allele that has been identified 
in the Amish community in Lancaster, PA (Desviat, Pérez et al. 2004, Strauss and Puffenberger 
2009). This mutation has been reported to be associated with a milder phenotype, therefore it is 
anticipated that these two subjects would have less severe symptomology. Subject 25 was 
diagnosed via abnormal NBS, was approximately 3 months of age at intervention and first face-
to-face contact with a metabolic physician; other clinical information is missing and/or unknown. 
Subject 28 was diagnosed by having a sibling with PA, was seen by a metabolic physician (at 20 
days of age) prior to intervention at 27 days of age, did not have any hospitalizations prior to 
intake in IBEM-IS at 18 years of age, and reportedly had a normal echocardiogram; other clinical 
information is missing and/or unknown. Precise genotype/phenotype correlations cannot be 
made in these two subjects because of the lack of clinical information, however homozygosity 
for the N536D allele may still be suggestive of the less severe outcome in these two adolescent 
subjects. In particular, Subject 28 did not have any hospitalizations at 18 years of age and had a 
normal echocardiogram, thus suggesting more mild disease.  
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6.1.4 Analysis of Service Utilization Data 
6.1.4.1 Content of the IBEM-IS Data at Intake 
A majority of the data in IBEM-IS was missing and/or unknown for all of the desired variables 
for this study. Sixty-seven to seventy-six percent of the health service, community resource, and 
provider data for each subject’s intake/consent visit was missing and/or unknown. A possible 
explanation as to why a large amount of the data is missing and/or unknown may be due to the 
process by which the data is currently being exported for statistical use. Through observation and 
reference to the original IBEM-IS protocol, it seems that when multiple visits are completed on a 
single day (i.e. an “intake” visit and an “interval” visit are to be collected on the day of 
enrollment) there is a dropout of some of the initial variables. Therefore, some of the desired 
variables for this study are considered missing and/or unknown because all of the information 
from both the “intake” visit and first “interval” visit were not included with the first 
measurement date. Efforts are being made to clarify the situation and allow for full access to this 
data. 
6.1.4.2 Content of the IBEM-IS Data for “Follow-up” Subjects 
The amount of missing and/or unknown data improved when the 18 “follow-up” subjects and 
their 106 visits were isolated from the dataset. A majority (83%) of the health services data was 
reported and/or documented. At this time, only limited interpretation of health service utilization 
for PA patients in IBEM-IS can be made. There may be other possible explanations for the 
differences in the number of times a particular service is reported. It is important to note in the 
following interpretations that services utilized are not weighted per individual, thus data may be 
biased due to certain services being used more by a small number of subjects. In these particular 
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cases, a precise distinction cannot be made between subjects enrolled in IBEM-IS for longer 
periods of time, subjects with more severe disease, and subjects that are more compliant with the 
proposed management guidelines. The tables representing the number of times a service is 
reported by a certain number of subjects are located in Appendix M-O.  
Overall, a high degree of variability was observed in the number of times subjects 
reported utilizing a particular service. Differences in the number of times a particular service was 
reported per subject may be due to the timeframe he or she was enrolled in IBEM-IS. Some 
subjects have been in IBEM-IS for more years than others. Those subjects who were enrolled for 
a longer period of time had more opportunities to report the types and number of times health 
services were utilized. Additionally, subjects with multiple visits entered in IBEM-IS are 
following-up with the participating metabolic center more often and may be more likely to 
follow-up with other health services more often, as well. Therefore it is possible that the years 
with the greatest proportion of newly enrolled subjects would have the least amount of services 
reported. This could be an explanation for the lack of service utilization data in 2007 and 2009. 
In the years 2012 and 2013 the proportion of new subjects entered into IBEM-IS was the least 
(0.23 and 0.22 respectively, Table 13); and as expected health services were reported the most in 
2012 and 2013 overall (Figure 10). This observation may also reflect that the majority of 
“intake” visits for newly enrolled subjects were seen to have missing and/or unknown data for 
health services, and therefore the least amount of services would be reported in the years with the 
most “intake” visits (i.e. newly enrolled subjects).  
Some subjects may require more extensive follow-up with a particular service due to the 
severity of the condition or specific symptomatology. Thus, the greater number of times a subject 
reports utilizing a certain service may be an indication of more severe symptomology/disease. 
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The services that were reported the most were cardiology, occupational therapy, physical 
therapy, neurology, speech-language therapy, and ophthalmology. The more common, chronic 
complications of PA including failure to thrive, developmental delay, various neurological 
symptoms, and cardiomyopathy are exemplary of the need for these services. Additionally, these 
particular services fit well within the clinical spectrum of PA and management guidelines 
reported in the literature. However, other recommended health services such as gastroenterology, 
immunology, and transplantation services were reported less often (Sutton, Chapman et al. 
2012). Only one subject reported using gastroenterology on 5 separate occasions. Immunology 
and transplantation services were not reported by any of the PA subjects in IBEM-IS (Appendix 
M). The reason for this may be that these specific services are associated with the more rare 
complications of PA such as acute pancreatitis, neutropenia, and the need for liver 
transplantation (Dionisi-Vici, Deodato et al. 2006, Sutton, Chapman et al. 2012).  
 There were instances in which a subject reported receiving a service only once and no 
other subjects reported using the same service. This was observed in the following health 
services: behavioral/developmental pediatrics, feeding therapy, home health care, surgery, and 
urology (Appendix M). Single reporting of a service may be attributed to the subject utilizing the 
particular service and then determining that the service is no longer needed. This may also be 
explained by a patient only having one visit documented in IBEM-IS and therefore he or she 
only had one opportunity to report this service.  
In further assessment of the content or amount of missing data for the 18 “follow-up” 
subjects, it was seen that almost half (46%) of the community resources data was still missing or 
unknown. Out of the subjects that had data documented for this variable, the response was 
“none” 41% of the time. Additionally, for the cases in which a specific community service was 
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reported more often it was attributed to only 1 or 2 subjects (Appendix N). The amount of 
missing and/or unknown data for the community resources received by the subject may be due to 
limited investigation of these components of care during routine metabolic appointments, either 
due to time constraints or because it is not part of the current medical management guidelines 
(Sutton, Chapman et al. 2012). Additionally, the question of community resources may not be 
raised in medical visits, assuming that it is addressed through the patients’ school system or other 
social services. However, if the data in IBEM-IS is truly representative of what PA patients are 
currently utilizing in terms of resources, it may be possible that families are unaware of the local 
community resources for which they are eligible. This uncertainty may have been clarified 
through the parent/guardian interviews, and speaks to the need for interaction with a social 
worker or genetic counselor in routine metabolic visits. Almost all (44/46) of the participants 
reported that genetic counseling was provided for their diagnosis of PA, however genetic 
counselors made up only 7% of the total reports for the “providers seen at this visit”. One of the 
many competencies of genetic counselors is to identify community resources and advocate for 
clients (Uhlmann, Schuette et al. 2009). This particular skillset would be useful at the time of 
diagnosis and also at each follow-up visit with the family to provide updated information in the 
context of changing clinical issues.  
A large majority (89%) of the “providers seen at this visit” data was reported and/or 
documented. All of the 18 “follow-up” subjects reported seeing a physician and dietician at their 
visit documented in IBEM-IS (Appendix O). This illustrates that the physician and dietitian are 
regarded as an integral part of the metabolic team.  
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6.2 IDENTIFICATION OF CURRENT SERVICE UTILIZATION AND 
COMPARISON OF SERVICE UTILIZATION DATA  
As a consequence of not being able to recruit participants for the study, the interview of 
parent/guardians of PA patients could not performed. By lacking data from the interview, current 
service utilization information in PA patients could not be assessed. Therefore the parent-stated 
service utilization data was not available to be compared to the documented aggregate data in 
IBEM-IS. The last two aims of the study were not achieved because of the inability to recruit 
subjects to interview for the study. The barriers to subject recruitment are discussed below.  
6.3 BARRIERS TO SUBJECT RECRUITMENT  
It is evident that much of the planned comparative work for this study could not be done due to 
difficulties encountered in recruiting patients/parents for the interview component of the study. 
Multiple barriers in study enrollment were the focus of a paper by Peters-Lawrence et al. (2012). 
A specific barrier to patient recruitment in rare disease research is a limited pool of available 
subjects. In addition, the amount of resources available to support the project can play a part in 
the success of study enrollment. Limited research staff, the lack of partnership with community 
organizations specific to the condition of interest, and the lack of formal recruitment strategies 
incorporating the use of media were all listed as potential barriers in subject recruitment (Peters-
Lawrence, Bell et al. 2012). 
Recruitment is one of the most challenging aspects of a clinical research study. 
Successful recruitment of patients is contingent on 4 factors: the design of the study, 
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collaboration with other healthcare professionals, characteristics of the study population, and the 
recruitment strategies put into place (Patel 2003, Peters-Lawrence, Bell et al. 2012). It is 
necessary that the design and method of the study be established at an early stage. The design 
and method can include factors such as appropriate length of the enrollment period, thoughtful 
inclusion/exclusion criteria for participants, expected duration of active participation by the 
subjects, and the risks and benefits of participation. Communication between/among 
collaborators is essential. All parties involved need to know exactly what they will be asked to 
do, their particular role in the study, the timeframe within which they are expected to work, and 
the results of study. It is important to be cognizant of the characteristics of the target patient 
population and to be flexible with potential participants. With rare disease research, investigators 
must acknowledge potential obstacles in subject enrollment. Lastly, successful subject 
recruitment rests primarily on the specific recruitment strategies implemented and the 
distribution of invitations to participate in the study (Patel 2003). To identify potential barriers of 
subject recruitment for this study, each of the four components of successful recruitment are 
examined.    
6.3.1 Design of the Study  
For this project, recruitment was particularly hindered because the design of the study included a 
short enrollment period. Originally, active enrollment of subjects was to begin July 2013, 
however the approval of the protocol by both the IRB and IBEMC took several months and 
therefore delayed the project. IBEMC only accepts IRB-approved protocols for submission and, 
in this study, after the protocol was approved by IBEMC several modifications then needed to be 
submitted to the IRB. Active enrollment of subjects was pursued from October 15, 2013 until 
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December 31, 2013 and this two-and-a-half month period was not sufficient to accomplish the 
goals of this study.  There was not sufficient time available to thoroughly exhaust all efforts of 
communication with the various site coordinators and the 2 potential subjects from the 
Children’s Hospital of Pittsburgh of UPMC.  
The inclusion criteria for the study were any IBEM-IS-consented PA patients, who were 
0-18 years of age, and who agreed to be re-contacted. The age restriction that was placed on the 
target population for this study excluded 15 out of the 46 PA patients that were entered in IBEM-
IS because they were 18 years of age and older. This was originally done because large sections 
of the telephone interview focused on interventions made within the school system and allowed 
the parent/guardians to elaborate on their answers concerning their satisfaction with the services 
offered and utilized.  
The intent stated in the invitation letters and the telephone consent form was that the 
duration of the telephone interview would be a minimum of 45 minutes. Although the total 
duration of participation was to be within one telephone call, it is possible that some subjects did 
not wish to speak on the phone for a longer period of time and this may had deterred them from 
participating in the study. Additionally, establishing contact with participants by telephone might 
require several attempts at different times and on different days, thus making the coordination of 
a telephone-based interview even more challenging (Patel 2003).  
There were no physical risks associated with this project. However, the interview may 
raise questions or concerns about the specialty health services that the child is currently 
receiving. The interview questions were drafted to address all of the potential services and 
resources and may not be applicable to all participants. The parents are encouraged to discuss 
these concerns with their child’s healthcare team. And interviews have the potential for causing 
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individuals to become uncomfortable discussing personal matters. The study was not designed to 
provide any direct benefits to the parent/guardian or their child. The primary benefit would have 
only been an increased knowledge base for the treatment of PA patients generally.  
6.3.2 Collaboration with Other Healthcare Professionals 
Precise and detailed instructions were provided to each of the site coordinators, however almost 
half of the sites did not respond after three attempts at contact were made. The reason for the 
poor response rate is not entirely known. However, given tight staffing limits and lack of 
financial remuneration for this study, it may have been given low priority among the 
participating centers’ many responsibilities.  Among the sites that did respond, a number 
indicated that they were no longer participating in IBEM-IS. Some responders stated that the site 
coordinator from the contact list was no longer working for their institution and thus that the 
initial contact letter was misdirected and not re-directed appropriately. Overall, there were 
challenges in obtaining current contact information for site coordinators and participating 
centers. There is a need to maintain up-to-date information within a public forum for those who 
wish to conduct research using IBEM-IS data.  
Additional means of communication, except for email, were not available to this 
investigator; however, the study was discussed by the Children’s Hospital of Pittsburgh site 
coordinator on a number of occasions during routine IBEMC team conference calls and during a 
face-to-face team meeting in the fall of 2013. Additional telephone and face-to-face 
conversations with individual site coordinators may have prompted a better response. Research 
suggests that widespread support from   the   organization in   which   the   study   is being 
implemented is important (Peters-Lawrence, Bell et al. 2012).  
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A major challenge that was faced in collaborating with other centers was differences in 
IRB protocols among the centers. With internal IRB approval of protocols, unless all 
participating centers originally submitted protocols with the same criteria, each center must write 
amendments and submit modifications to their own IRB if protocol changes are made, 
particularly as it relates to recontacting patients, as occurred in this study. This process 
drastically slowed down progress when attempting to recruit IBEM-IS-consented subjects from 
other institutions. It has been suggested that moving to a single, umbrella IRB for collaborative 
projects would help overcome such challenges (Marsolo 2012).   
6.3.3 Study Population  
Propionic acidemia is defined as a “rare” or “orphan” disease, affecting fewer that 650 per 
1,000,000 people in the US. In fact, it more correctly could be termed an “ultra-rare” disease, a 
term more recently applied to conditions that affect fewer than 20 per 1,000,000 people in the 
US. There is a low prevalence of individuals with the disease and the research and treatments 
related to the specific condition are sparse (Griggs, Batshaw et al. 2009). Research in rare 
diseases is often hindered by inadequate subject recruitment. For this reason, there is a need for 
multi-center collaborations to identify and recruit PA patients (Griggs, Batshaw et al. 2009). 
Currently at the Children’s Hospital of Pittsburgh of UMPC, there are a total of three PA 
patients. Two of these fit into the inclusion criteria for the study, being 0-18 years of age, and 
one patient had just turned age 18 at the time of enrollment. Active participation by 26 other 
IBEM-IS centers was necessary for adequate subject enrollment.  
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6.3.4 Recruitment Strategies  
It was necessary to go through a third party (i.e. the metabolic center known to the patients) to 
recruit subjects in order to maintain patient confidentiality. Further, individual patients are not 
identified to all Collaborative participants, in compliance with HIPAA regulations for personal 
health information. While confidentiality was maintained with our recruitment strategy, it posed 
a significant barrier to informing participants about the present study. Without participation by 
the metabolic centers and site coordinators affiliated with IBEM-IS, it was not possible to 
contact patients, inform them about the details of the study and invite subjects to participate in 
the study. The ability to use different methods of communication with potential participants, 
including mailed letters, telephone calls, e-mail correspondence, or face-to-face contact may 
have helped to increase the participation rate (Patel 2003). 
6.4 STUDY LIMITATIONS 
6.4.1 The Inborn Errors of Metabolism Information System (IBEM-IS)  
The amount of missing and/or unknown data in the database posed a limitation in the analysis of 
the data. The amount data present in the database may be due to the process by which the data is 
currently being entered in IBEM-IS and exported for statistical use. The data present in IBEM-IS 
is information that is extracted from patients’ medical records. Site coordinators and health 
professionals from the various participating centers enter the information into the database. If the 
necessary information is not documented in the subject’s medical record, then it is not possible to 
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enter it into IBEM-IS. The site coordinators are thus potentially limited in their ability to abstract 
information and to enter complete sets of data for each subject if the data is not included in the 
clinical record 
The data that is available to be entered into IBEM-IS is dependent on a number of 
different factors. The amount of information within in a patient’s medical record is 
predominately determined by the provider with his or her visit documentation. Some providers 
may not dictate all of the patients’ information that was discussed at each visit, especially with 
respect to other health service utilization and community resources received. Also, in the cases in 
which a particular subject is routinely following up with his/her provider, the provider may not 
document which health services are being used at each visit because this information is already 
understood and known to the provider. Patients may also not feel the need to report which health 
services are currently being used at each metabolic visit and therefore, the result is an 
underreporting of services. 
A limitation in the analysis of the IBEM-IS data is that subjects who are first entered into 
IBEM-IS may or may not be new to the participating metabolic center. Data is collected from 
each subject at enrollment and is labeled as the intake visit even when the subject has been 
following-up with the metabolic center for a number of years. Therefore, the information 
documented for each subjects’ intake visit cannot be regarded as baseline information. As the 
subjects are followed over time, clinical visits may focus on unique issues and not be as 
comprehensive as early visits. Thus, all of the components of the IBEM-IS surveys may not be 
addressed during follow-up visits. Additionally, the information present in IBEM-IS is based on 
opportunistic data collection practices and subjects are not obligated to report data on a routine 
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basis. For this reason, the data in IBEM-IS may not be truly representative of complete 
longitudinal information.  
Another limitation in the analysis of the IBEM-IS data was the number of subtle 
differences in documentation among participating centers. There was not consistency in 
documentation especially for data fields in which information was “written-in” such as ethnicity, 
mutation description, and specific comorbidities. In some cases, the data needed to be rewritten, 
reorganized, and categorized for harmonization. Given that IBEM-IS is a relatively new database 
for the collection of clinical information for patients with an inborn error of metabolism, it seems 
possible that there are some challenges in the process by which the data is exported for statistical 
use. In particular, it seems that when multiple visits are completed on a single day (i.e. an 
“intake” visit and an “interval” visit are to be collected on the day of enrollment per protocol) 
there is a dropout of some of the initial variables. Therefore, some of the desired variables for 
this study may be considered missing and/or unknown.  Efforts are being made to clarify the 
situation and allow for full access to this data. 
6.4.2 DocSite vs. REDCap 
Challenges were faced in the merging of the data within DocSite and REDCap because the two 
databases have different data collection platforms. The data reporting practices in DocSite 
require the user to type in the information for all available fields, while REDCap is built with a 
more sophisticated entry process. The data entry in REDCap involves branching logic and a 
series of pull-down menus. Also, the two data collection platforms contained different variables 
and different titles for variables that they had in common.  
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In addition to the differences in data entry between the two databases, there were also 
differences in the data output. DocSite data was exported with the data variables listed in a word 
format. Each visit had its own row and every variable had its own column. There was a new 
column for every additional data entry per variable. The REDCap data was exported in a coded 
format (0=yes, 1=no, etc.), which required the use of a data dictionary. Each visit had its own 
row and every potential entry for each variable had its own column. There was a need to develop 
and write macros to translate the data in REDCap for qualitative analysis purposes, causing 
additional unanticipated delays in being able to manipulate the data. 
As a result of the aforementioned difficulties, there were limitations in the analysis of the 
combined data. One limitation was the shortened list of variables provided for analysis. The full 
list of desired variables was not provided in a combined format because the merging of the 
databases excluded some variables that were not present in both databases.  As noted, another 
limitation was the amount of time for analysis of the combined data. Managing the data output 
from REDCap and merging the two databases required a substantial amount of time to be 
completed, thus taking away from the time spent on analysis.  
6.4.3 Telephone Interviews of PA Subjects 
Telephone interviews were to be conducted with parents and/or guardians of PA patients to 
determine which healthcare services PA patients are using and to identify the parent’s current 
perception of unmeet needs in his/her child. While the second aim of this study was not 
achieved, potential benefits and limitations in the implementation of telephone interviews are 
discussed.  
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Interview methods allow investigators to explore matters in greater depth and can be a 
useful tool in gathering large amounts of information from respondents. This approach is 
particularly useful for the types of questions that were to be asked in this study. Intended 
questions were aimed at the parents’ satisfaction with the care that their child receives, their 
experience in accessing treatment, how well the healthcare providers understand their child’s 
condition, if any providers were especially responsive to their child’s needs, and if they felt that 
any of their child’s medical needs were not being adequately addressed. Therefore, through an 
in-depth interview and open dialogue, comprehensive data would have been collected from the 
participating parents. With this information, unmet needs of the patient would have been 
discerned. Furthermore, telephone interviews typically attain higher response rates than postal 
questionnaires (Sibbald, Addington-Hall et al. 1994).  
A potential limitation of telephone interviews may be the nature of the responses 
obtained by such a method and a potential for bias. Some studies suggest that responses from 
interviewees may be influenced by the relationship between the interviewer and the responder 
and therefore are presumably more susceptible to a social desirability response bias (Patel 2003). 
Other studies conclude that the nature of responses differs little between face-to-face, telephone, 
and postal administration of questionnaires (Sibbald, Addington-Hall et al. 1994). These 
possibilities can be assessed in future comparative studies (below). It had been observed that the 
nature of responses obtained in an interview or survey can vary based on the individual reporting 
the information. Parent or guardian-reported data was examined in a study by Bailey et al. 
(2010). It was determined that variability in accuracy exists in the information gathered from 
parents or guardians. The data that was presumably the most accurate was information that can 
only be reported by parents or information perceptual in nature. Such factors were living 
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conditions, relationships, recreational activities, quality of life, and family stress (Bailey, Raspa 
et al. 2010). Recall bias can also be a limitation in parent or guardian-reported data. It can be 
difficult for parents to remember all of the details about events, medical interventions, and 
specialty health care visits after many years have passed. The study hoped to address these 
possibilities by comparing the parent-reported information to the data recorded into IBEM-IS 
from the review of medical records.  
6.5 FUTURE STUDIES  
Due to the inability to recruit participants for the study in a shortened time frame, continuation of 
the proposed study including conducting the telephone interview of parents/guardians of PA 
patients to discern health service utilization and unmet needs is desirable. Alternative steps can 
be taken in future studies to facilitate the recruitment process. Future studies may include PA 
patients of all ages to expand the target population. Separate interview documents can be created 
to address the needs of each age group (i.e. early intervention services, school-related services, 
transitional services, and adult services). It would be interesting to learn which services PA 
patients require at different stages of life. The list of interview questions could be drafted to be 
concise for the variables pertaining to each age group, thus shortening the interview time with 
the subject and also allowing for a greater number of respondents. Additionally, there may be 
consideration of recruiting PA patients outside of IBEM-IS for interview purposes. With this 
approach, future areas of study would focus on analyzing the interview/questionnaire data only 
without a comparison to the data collected in IBEM-IS. Future researchers may use a similar 
approach as the study done by Pena et al. in 2012, by distributing a survey among Propionic 
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Acidemia Foundation (PAF) members or a similar organization. Investigators may also consider 
alternative approaches to telephone interview that might help improve recruitment, such as e-
mail correspondence and online forums to accommodate for participants with busy schedules.   
 Additional questions remain relating to health and community-based service utilization 
by PA patients and their families. Future studies may place more of an emphasis on the 
community resources that are available to PA patients and their families and work to gather 
information and to inform families of suitable support resources. After current service and 
resource utilization information is obtained from PA patients, further exploration into potential 
regional and ethnic differences in healthcare utilization would be a compelling area of research. 
Such factors may affect availability of and access to multidisciplinary healthcare and 
community-based services. Although limited by a small patient population, future research may 
focus on identifying the potential differences in service utilization and the community resources 
offered to PA patients across the various metabolic centers in the United States.  Also, due to the 
higher incidence of PA in certain Amish communities, it would be interesting to learn which 
services this specific patient population has access to and, out of these services, which ones 
members of the Amish community find most useful.     
 76 
7.0  CONCLUSION 
This present study examined the PA patient data collected in IBEM-IS with respect to the 
anticipated needs of PA patients based on the clinical spectrum and compared them to 
anticipated needs based on current practice guidelines reported in the literature. The assessment 
of the PA data in IBEM-IS showed that the majority of the necessary variables were missing 
and/or unknown. Thus, only a preliminary interpretation of service utilization in PA patients was 
performed.  
All of the PA subjects in IBEM-IS with documented follow-up visits reported seeing a 
physician and dietician. This acknowledges that the physician and dietitian are regarded as 
integral parts of the metabolic team. The specialty health services that were reported the most in 
PA patients with documented follow-up visits were cardiology, occupational therapy, physical 
therapy, neurology, speech-language therapy, and ophthalmology. These particular services fit 
well within what is needed based on the clinical spectrum of PA and the management guidelines 
reported in the literature (Sutton, Chapman et al. 2012). The more common, chronic 
complications of PA including failure to thrive, developmental delay, various neurological 
symptoms, and cardiomyopathy are exemplary of the need for the aforementioned services 
(Pena, Franks et al. 2012). However, other recommended health services, such as 
gastroenterology, were seldom reported, and immunology and transplantation services were not 
reported by any of the PA subjects in IBEM-IS. The reason for this may be that these specific 
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services are needed to address the more rare complications of PA such as acute pancreatitis, 
neutropenia, and liver transplantation due to recurrent episodes of hyperammonemia or acidosis 
not adequately controlled with medical therapies (Sutton, Chapman et al. 2012). Current 
information regarding community resources for PA subjects in IBEM-IS is limited. It is possible 
that these resources are not routinely documented as part of medical management because they 
are not part of the current medical management guidelines. However, if the data in IBEM-IS is 
truly representative of community resource utilization in PA patients, it may be possible that 
families are unaware of the local community resources for which PA patients are eligible.  This 
highlights the need for a social worker or genetic counselor to be part of routine metabolic visits. 
The two remaining aims were not achieved in this study due to challenges in subject 
recruitment. The original intent was to interview parents and/or guardians of PA patients to 
identify current service utilization and to compare the parent/guardian-reported service 
utilization data to aggregate data in IBEM-IS. There are two possible outcomes of the data 
comparison 1) Patients are accessing health services as reported to IBEM-IS or 2) Patients are 
accessing more health services than are documented in IBEM-IS. In the later scenario, the 
differences between the two sets of service utilization data may be due to patients accessing but 
not disclosing more services than are documented in IBEM-IS. On the other hand, the 
differences may be due to the current data collection and entry practices in the IBEM-IS. We had 
hoped to elucidate the actual cause from our analysis of collected data. 
Despite the limitations due to the absence of subject recruitment, the analysis of the 
information collected from PA patients in IBEM-IS helps to build upon the existing database and 
will assist in promoting future research studies. By identifying the amount of missing and/or 
unknown information present in the database and by touching upon the correlations observed in 
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service utilization to date, the results of this study may aid in further development of effective 
longitudinal studies of PA patients. In addition, the study may provide insight into whether 
current patients are accessing and utilizing clinical and community based services and whether 
additional emphasis needs to be placed on these services by clinicians. Due to the rarity and 
heterogeneity of the condition, there is little known about the current health services being 
utilized by patients with PA and thus a continued need for uniform data collection practices and 
more detailed assessment of these patients. With knowledge of the specific health services most 
useful to PA patients and by identifying which services they are not accessing there is 
advancement in establishing care recommendations across various centers nationwide.  
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APPENDIX A 
FACILITIES WITH IRB APPROVAL TO ENROLL PATIENTS IN IBEM-IS 
State Facility 
AR Children's Hospital - Genetics 
IA University of Iowa Children's Hospital 
IL Ann and Robert H. Lurie Children's Hospital of Chicago 
IL University of Illinois at Chicago 
IN Indiana University Department of Medical and Molecular Genetics 
KY University of Louisville 
MD Johns Hopkins 
MI University of Michigan 
MI Wayne State University 
MN University of Minnesota 
MO University of Missouri 
NC Duke University 
NE University of Nebraska 
NJ Hackensack University 
NY Children's Hospital at Montefiore 
NY New York Medical College 
NY University of Rochester 
NY Women and Children's Hospital of Buffalo 
OH Cincinnati Children’s Hospital Medical Center 
OH Nationwide Children's Hospital 
OK Saint Francis Hospital 
OK University of Oklahoma 
SD Sanford Children's Specialty Clinic 
WI Medical College of Wisconsin 
WI University of Wisconsin 
WV West Virginia University 
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Amino Acidemias 
 
Maple syrup urine disease 
Homocystinuria (CBS, MTHFR, Cbl D variant 1, Cbl E, Cbl G 
Tyrosinemia 
Arginemia 
Argininosuccinate acidemia ( Yorifuji, Kawai et al.) 
Citrullinemia Type I (argininosuccinate synthetase) 
Citrullinemia Type II (citrin deficiency) 
Hypermethioninemia 
Defects of biopterin cofactor biosynthesis/regeneration 
Hyperphenylalaninemia/phenylketonuria 
Fatty Acid Oxidation 
Disorders 
 
Carnitine uptake deficiency (CUD) 
CACT deficiency 
CPT-1 deficiency 
CPT-2 deficiency 
SCAD deficiency 
SBCAD deficiency 
MCAD deficiency 
LCHAD deficiency 
Trifunctional protein deficiency 
VLCAD deficiency 
Dienoyl-CoA reductase deficiency 
Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT) 
Glutaric acidemia type II 
Medium/Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency 
(M/SCHAD) 
Organic Acidemias 
2-methylbutyryl-CoA dehydrogenase  deficiency 
Isovaleric acidemia 
Glutaric acidemia type I 
Isobutyryl-CoA dehydrogenase deficiency 
3-MCC deficiency 
2-methyl 3-hydroxybutyryl CoA dehydrogenase (2M3HBA) deficiency  
Holocarboxylase synthetase deficiency 
3-methylglutaconic aciduria type I 
Beta-ketothiolase deficiency 
Succinyl CoA-3-keto transferase (SCOT) deficiency 
3-hydroxy 3-methylglutaryl (HMG) CoA lyase deficiency 
Propionic Acidemia 
MMA (Mut-, Mut0, cbl A, cbl B, cbl D variant 2) 
MMA + Hcy (Cbl C, Cbl D, Cbl F, Transcobalamin II) 
Malonic acidemia 
Non-MS/MS 
Conditions 
Biotinidase deficiency 
GALT deficiency 
Galactokinase (GALK) deficiency galactosemia 
UDP-galactose-4-epimerase (GALE) deficiency galactosemia 
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APPENDIX D 
DATA REQUESTED FOR THE STUDY 
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IBEM-IS Data Requested for the Study 
 
Propionic Acidemia Intake: 
• Demographics   
o Specify ethnicity if ethnicity is listed as “other”, enter N/A if not applicable  
• Socioeconomic Status  
o Maternal education: highest level of education  
o Paternal education: highest level of education 
o Is patient/primary caregiver proficient in written English? 
o Is patient/primary caregiver proficient in spoken English? 
• Diagnostic Testing  
o Molecular Testing: Common or target mutation panel  
o Molecular Testing: Full sequencing  
o Mutation description: Allele 1 (format example 985A>G) 
o Mutation description: Allele 2 (format example 985A>G) 
• Past Health History  
o Number of hospitalizations prior to Intake in IBEM-IS 
o Initial diagnosis of this IBEM-IS found by: 
o Days of age from birth to initiation of intervention for this IBEM (365 x yrs or 30 x months or counted 
days), enter 99999 if unknown 
o Symptom(s) at time of initial metabolic contact  
o Days of age at time of initial face to face metabolic consultation (365 x yrs or 30 x months or counted 
days), enter 99999 if unknown 
o Was genetic counseling for this disorder provided? 
o Echocardiogram results obtained prior to Intake: enter date of echo and explain results, enter N/A if not 
applicable  
o Identify specific birth defects  
o List specific comorbidities (enter N/A if not applicable, enter unknown if missing information) 
 
Propionic Acidemia Interval: 
• Demographics 
o Patient has attended an outpatient metabolic visit during the past 12 months?  
o Metabolic follow up status 
o Primary care status  
• Socioeconomic Status  
o Current insurance status  
• Past Health History  
o Has patient had surgical procedure(s) since the last outpatient metabolic visit? 
o Has patient received dialysis since the last outpatient metabolic visit  
o List specific comorbidities (enter N/A if not applicable, enter unknown if missing information) 
• Emergency Management  
o Number of ER visits since last metabolic visit 
o Number of hospital admission (total) since last metabolic visit 
• Care Coordination 
o Other health services received currently  
o Community resources received currently  
o Providers seen at this metabolic visit  
o Other providers seen at this metabolic visit (enter N/A if not applicable) 
• Developmental Assessment 
o Developmental screening occurred at this visit? 
o Developmental milestones achieved at this time? 
o If developmental milestone(s) not achieved, which one(s) were not achieved? 
o If developmental milestone(s) not achieved, was patient referred for further developmental evaluation?  
o Was neuropsychological evaluation done since last outpatient visit? (If yes, complete Neuropsych 
Survey) 
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o Overall neuropsychological testing impression (from most recent neuropsych evaluation) 
o Are behavioral concerns suspected as this time? 
o If behavioral concerns are suspected at this time, explain (enter N/A if no behavioral concerns suspected) 
o If behavioral concerns are suspected at this time, was patient referred for further evaluation?  
• Education 
o Was patient referred for Special Education evaluation at this time? 
o Are Special Education services received by this patient currently? 
o Special Education services are received currently: age (in years) child qualified for services? 
o Reason Special Education services are received currently? 
• Laboratory Studies 
o Molecular Testing: Common or targeted mutation panel done at this visit (enter specific mutation(s) on 
Intake Survey)? 
o Molecular Testing: Full sequencing done at this visit (enter specific mutation(s) on Intake Survey)? 
• Imaging Studies 
o Abdominal imaging done since last outpatient metabolic visit? 
o Cardiac imaging done since last outpatient metabolic visit? 
o Musculoskeletal imaging done since last outpatient metabolic visit? 
o Dexa scan since last outpatient metabolic visit (z-score >-2), specify site? 
o Neurological imaging done since last outpatient metabolic visit? 
o Renal/pelvic/genital imaging done since last outpatient metabolic visit? 
o Other imaging (indicate type of imaging and if WNL or Abn) done since last outpatient metabolic visit?, 
enter N/A if not applicable 
• Nutrition   
o Method of payment for low protein foods, if prescribed 
o Method of payment for metabolic formula, if prescribed 
o If other nutritional supplementation is taken (explain), enter N/A if not applicable 
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RedCap Data Requested for the Study  
 
• Demographics Information (page 2) 
o Age 
o Societal sex 
• Condition (page 2) 
o Patient condition category  
o Specify organic acid disorder diagnosis for the patient  
o Patient disorder identification method 
o Family member with this condition 
• Care and Other Studies (page 2) 
o Miles from home to primary care 
o Miles from home to specialty care 
o Specify type of primary care provider  
o Specify medical home  
o Specify medical home-other, specify 
• Education (page 3)  
o Maternal education 
o Paternal education 
o Patient education 
o Special education services received prior to intake 
o Age patient qualified for special education services 
• Ancestral Origin, Race and Ethnicity (page 4) 
o Ancestral Origin 
o Ancestral Origin-Africa 
o Ancestral Origin-Asia 
o Ancestral Origin-Europe 
o Ancestral Origin-North America 
o Ancestral Origin-South America 
o Ancestral Origin-Oceania 
o Ancestral Origin-Other 
o Race 
o Patient is Hispanic or Latino 
• Medical Coverage (page 5) 
o Medical coverage at time of intake 
o Medical coverage at intake-Patient assistance program, specify 
o Medical coverage at intake-Other, specify 
• Language (page 6)  
o Primary language spoken at home 
o Written/web-based information on this condition provided to the patient/primary caregiver in his/her 
primary language 
• Prenatal History (page 16) 
o Prenatal diagnosis done for this condition 
o Form of prenatal diagnosis 
• Neonatal history (page 17) 
o Congenital anomalies 
! Type of congenital anomalies 
o Neonatal complications 
! Type of neonatal complications  
• Health History (page 19) 
o Patient has had an outpatient specialty visit 
o Days of age from birth until intervention for this condition 
o Days of age from birth until first seen by subspecialist 
o History of premature ovarian insufficiency (POI)  
o History of coenzyme Q10 or OXPHOS deficiency  
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o History of renal failure 
• Dialysis (page 19)  
o Dialysis (any type) prior to intake 
• Transplants (page 19) 
o Transplant prior to intake 
• Other History (page 19) 
o Cardiomyopathy prior to intake 
o Hospitalizations prior to intake 
o Number of hospitalizations prior to intake related to this condition 
o Number of hospitalizations prior to intake not related to this condition 
o Genetic counseling provided 
o Provider of genetic counseling 
o Comorbidities at time of intake 
• Prior Testing (page 20) 
o Echocardiogram prior to intake 
o Neurological imaging prior to intake 
o History of a seizure disorder 
• Eye Exam (page 21) 
o Eye exam performed prior to intake 
o Eye exam findings 
• Status at time of NBS report to Specialist (page 26) 
o Patient symptoms at initial contact 
• Genetic Testing (page 32) 
o Type of genetic/genomic testing 
o Gene(s) associated with PROP PCCA PCCB Other 
o Gene(s) associated with PROP-other, specify 
o PCCA: Specify allele 1 
o PCCA: Specify allele 2 
o PCCB: Specify allele 1 
o PCCB: Specify allele 2 
o Other: Specify allele 1 
o Other: Specify allele 2 
• Education (page 34) 
o Education status has changed since the last visit 
• Care and Other Studies (page 34) 
o Providers seen at this visit 
o Providers seen at this visit, other- specify 
• Medical Coverage (page 34) 
o Medical coverage at visit 
o Medical coverage at visit-Patient assistance program, specify 
o Medical coverage at visit-Other, specify 
• Health Status (page 36)  
o Current comorbidities 
• Sick Visits (page 36) 
o Sick visits since last outpatient visit 
o Number of sick visits 
o Reason for sick visit 1-10 
o Patient was admitted to the hospital as a result of sick visit 1-10 
o Number of inpatient days for sick visit 1-10 
• Procedures (page 40) 
o Anesthesia since last visit 
o Surgeries since last visit 
• Dialysis (page 41) 
o Dialysis (any type) since the last outpatient metabolic visit 
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• Care Coordination (page 44) 
o Other health services currently received 
o Specify other current health services 
o Specify other current health services-other, specify 
o Specify type of primary care provider 
o Community resources currently received 
o Specify current community resources 
o Specify current community resources-other, specify 
o Specify current family support 
o Specify current family support-other, specify 
o Specify medical home 
o Specify medical home-other, specify 
o Specify current social services 
o Specify current social services-other, specify 
• Developmental Assessment (page 45) 
o Developmental assessment done at this visit 
o Developmental status 
o Severity of atypical development 
o Referred for further developmental assessment 
o Type of provider/service to whom patient was referred for developmental assessment 
o Type of provider/service to whom patient was referred for developmental assessment-other, specify 
o Neuropsychometric evaluation performed since last visit 
o Patient has mental health concerns 
o Referred for further mental health assessment 
o Type of provider/service to whom patient was referred for mental health assessment 
o Type of provider/service to whom patient was referred for mental health assessment-other, specify 
o Behavioral concerns 
o Referred for further behavioral assessment 
o Type of provider/service to whom patient was referred for behavioral assessment 
o Type of provider/service to whom patient was referred for behavioral assessment-other, specify 
• Education (page 47) 
o Special education assessment recommended 
o Reason special education services received 
o Reason special education services received-other, specify 
o Special education category 
o Special education, other- specify 
• Nutrition (page 65) 
o Number of special metabolic formulas recommended/prescribed 
o Method of payment for special metabolic formula 1-3 
o Modified low protein foods recommended/prescribed 
o Method of payment for modified low protein foods 
• Number of different episodes during which dialysis (any type) was used (page 151) 
• Number of organ transplants received (page 164) 
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 !
 
 
Dear [Site Coordinator Name],  
 !
You are receiving this letter because you are a site coordinator for the Inborn Errors of Metabolism 
Information System (IBEM-IS) research registry at [location].  
 
A new study has been reviewed and approved by IBEMC to review and assess the information being 
gathered about propionic acidemia patients regarding service utilization. We are looking at what 
services are currently being used, how they are being reported and recorded during clinic visits, and 
whether there are services that might still be needed by patients and families. Participation in the study 
will involve a telephone interview of the parents/guardians of children with propionic acidemia who 
have consented to participate in IBEM-IS. This interview will take about 45 minutes and will involve a 
series of questions regarding resources and services that the patient uses. A copy of the interview script 
and questionnaire are available upon request (see contact information below). 
 
The subjects who will be approached about their willingness to be interviewed are the 
parents/guardians of patients with a diagnosis of propionic acidemia who are 0-18 years of age, and 
who as part of their consent to IBEM-IS, have agreed to be re-contacted about new related research 
that is of interest to propionic acidemia patients and their families.  
 
A letter of invitation to the parents/guardians of the designated patients is attached. As a site 
coordinator, if you would please send this letter to your patients that meet the above criteria in a timely 
manner, it would be greatly appreciated.  
 
This study is being conducted by Georgianne Arnold, MD, the Principal Investigator of the IBEM-IS 
research registry in Pittsburgh, PA. The interview is being conducted by Amanda Jacquart, candidate 
for a Master’s degree in Genetic Counseling from the University of Pittsburgh. Please contact Amanda 
or Cate Walsh Vockley, MS, CGC to disclose the number of patients you have who meet the inclusion 
criteria for the study and to confirm that the enclosed letter of invitation has been sent to the 
parents/guardians of these patients.  
 
Thank you for your participation in this effort. 
 
 
Sincerely,  
 
 
Georgianne L. Arnold, MD 
Clinical Director 
Division of Medical Genetics 
Children's Hospital of 
Pittsburgh of UPMC 
 
 
Cate Walsh Vockley, MS, CGC 
Senior Genetic Counselor 
Division of Medical Genetics 
Children's Hospital of  
Pittsburgh of UPMC 
Phone: (412) 692-7349 
catherine.walshvockley@chp.edu 
Amanda J. Jacquart, BS 
Graduate Student Researcher 
Children's Hospital of 
Pittsburgh of UPMC 
Phone: (412) 692-6770 
amanda.jacquart@chp.edu 
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YOUR INSTITUTION’S LETTERHEAD 
 
[Address] 
[Address] 
[Address] 
[Address]  
 
 
Today’s Date, 2013 
 
 
Dear Parent/Guardian of [Patient Name],  !!
Thank you for participating in the Inborn Errors of Metabolism Information System (IBEM-IS) 
research registry at [Institution Name]. As part of the registry, you agreed to be re-contacted 
about new related research studies that are of interest to propionic acidemia patients and their 
families.  
 
Please read the enclosed invitation letter from our partners at the Children’s Hospital of 
Pittsburgh of UPMC for details concerning a new study. If you wish to participate in this study 
or if you have additional questions, the contact information for the research team at the 
Children’s Hospital of Pittsburgh can be found in the invitation letter and it is also listed below:  
 
Cate Walsh Vockley, MS, CGC 
Senior Genetic Counselor 
Division of Medical Genetics 
Children's Hospital of Pittsburgh of UPMC 
Phone: (412) 692-7349 
catherine.walshvockley@chp.edu 
Amanda J. Jacquart, BS 
Graduate Student Researcher 
Children's Hospital of Pittsburgh of UPMC 
Phone: (412) 692-6770 
amanda.jacquart@chp.edu 
 
 
Thank you for considering participation in this study. 
 
Sincerely,  
 
 
 
[Site Coordinator Name] 
[Credentials] 
[Etc.] 
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[Address] 
[Address] 
[Address] 
[Address]  
 
Dear Parent/Guardian of [Patient Name],  !
You are receiving this letter because your child is currently participating in the Inborn Errors of 
Metabolism Information System (IBEM-IS) research registry at [Institution Name]. As part of the 
registry, you agreed to be re-contacted about new related research studies that are of interest to 
propionic acidemia patients and their families.  
 
A new study is being done to review the information regarding service utilization that has been 
gathered as a part of the IBEM-IS research registry. This study will focus on children 0-18 years of age 
who have propionic acidemia. We are looking at what services are currently being used, how they are 
being reported and recorded during clinic visits, and whether there are services that might still be 
needed by patients and families. Participation is this study will involve a telephone interview of the 
parent/guardian with our study coordinator. This interview will take about 45 minutes and will involve 
a series of questions regarding resources and services that your child uses.  
 
There are no physical risks associated with this project, and this study is not designed to provide any 
direct benefits to you or your child. This interview may, however, raise questions or concerns about 
your child’s current needs that you may wish to discuss with your child’s healthcare team.  
 
All responses to the interview questionnaire are confidential. Information will include your child’s age, 
but your child and you will not be identifiable in any other way. Your participation is voluntary, and 
you may withdraw from this project at any time.  
 
This study is being conducted by Georgianne Arnold, MD, the Principal Investigator of the IBEM-IS 
research registry in Pittsburgh, PA. The interview will be conducted by Amanda Jacquart, a candidate 
for a Master’s degree in Genetic Counseling at the University of Pittsburgh, under Dr. Arnold’s 
supervision. Please contact Amanda by calling her at 412.692.6770 to confirm your willingness to 
participate in this study, or if you have additional questions. Thank you for considering this 
opportunity to help us improve patient care. 
 
Sincerely,  
 
 
 
Georgianne L. Arnold, MD 
Clinical Director 
Division of Medical Genetics 
Children's Hospital of  
Pittsburgh of UPMC 
 
 
 
Cate Walsh Vockley, MS, CGC 
Senior Genetic Counselor 
Division of Medical Genetics 
Children's Hospital of  
Pittsburgh of UPMC 
Phone: (412) 692-7349 
catherine.walshvockley@chp.edu 
 
Amanda J. Jacquart, BS 
Graduate Student Researcher 
Children's Hospital of  
Pittsburgh of UPMC 
Phone: (412) 692-6770 
amanda.jacquart@chp.edu 
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[Address] 
[Address] 
[Address] 
[Address]  
 
Dear Parent/Guardian of [Patient Name],  !
You are receiving this letter because your child is currently participating in the Inborn Errors of 
Metabolism Information System (IBEM-IS) research registry at Children’s Hospital of Pittsburgh of 
UPMC. As part of the registry, you agreed to be re-contacted about new research studies that are of 
interest to propionic acidemia patients and their families.  
 
A new study is being done to review the information regarding service utilization that has been 
gathered as a part of the IBEM-IS research registry. This study will focus on children 0-18 years of age 
who have propionic acidemia. We are looking at what services are currently being used, how they are 
being reported and recorded during clinic visits, and whether there are services that might still be 
needed by patients and families. Participation is this study will involve a telephone interview of the 
parent/guardian with our study coordinator. This interview will take about 45 minutes and will involve 
a series of questions regarding resources and services that your child uses.  
 
There are no physical risks associated with this project, and this study is not designed to provide any 
direct benefits to you or your child. This interview may, however, raise questions or concerns about 
your child’s current needs that you may wish to discuss with your child’s healthcare team.  
 
All responses to the interview questionnaire are confidential. Information will include your child’s age, 
but your child and you will not be identifiable in any other way. Your participation is voluntary, and 
you may withdraw from this project at any time.  
 
This study is being conducted by Georgianne Arnold, MD, the Principal Investigator of the IBEM-IS 
research registry in Pittsburgh, PA. The interview will be conducted by Amanda Jacquart, a candidate 
for a Master’s degree in Genetic Counseling at the University of Pittsburgh, under Dr. Arnold’s 
supervision. Please contact Amanda by calling her at 412.692.6770 to confirm your willingness to 
participate in this study, or if you have additional questions. Thank you for considering this 
opportunity to help us improve patient care. 
 
Sincerely,  
 
 
 
Georgianne L. Arnold, MD 
Clinical Director 
Division of Medical Genetics 
Children's Hospital of 
Pittsburgh of UPMC 
 
 
Cate Walsh Vockley, MS, CGC 
Senior Genetic Counselor 
Division of Medical Genetics 
Children's Hospital of  
Pittsburgh of UPMC 
Phone: (412) 692-7349 
catherine.walshvockley@chp.edu 
Amanda J. Jacquart, BS 
Graduate Student Researcher 
Children's Hospital of 
Pittsburgh of UPMC 
Phone: (412) 692-6770 
amanda.jacquart@chp.edu
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Telephone Consent Script:  
 
Thank you for agreeing to be re-contacted concerning new research that is being done 
with propionic acidemia patients who are registered with the Inborn Errors of Metabolism 
Information System (IBEM-IS).  
 
The purpose of this research study is to assess the information being gathered as a part of 
IBEM-IS from propionic acidemia patients and their families regarding service 
utilization. The outcome of this study will identify additional services that may be 
beneficial to propionic acidemia patients. 
 
The study will involve a telephone interview of parents of the propionic acidemia patient 
population that already consented to the IBEM-IS protocol. This interview will take a 
minimum of 45 minutes.  
 
While there are no physical risks associated with this project, this study is not designed to 
provide any direct benefits to you or your child. This interview may raise questions or 
concerns about your child’s current needs that you may wish to discuss with your child’s 
healthcare team. The interview will be audio recorded so that the PI can listen to the 
recording for data analysis. The audio recordings will be saved as MP3 files and the 
recordings will be transcribed into Word documents. The files will be maintained on a 
password-protected computer and will be kept until the conclusion the study and then 
destroyed. All responses are confidential, and results will be kept in a password-protected 
file. Information will include your child’s age, but your child will not be identifiable in 
any other way. Your participation is voluntary, and you may withdraw from this project 
at any time. Even after this interview has concluded, you can later inform us that you 
have decided to withdraw from this study.  However, the information that we have 
collected before you tell us that you are withdrawing will continue to be used. 
 
If you are willing to participate, I am going to ask a series of questions regarding 
resources and services that your child uses. The purpose of this interview is to assess 
propionic academia patient’s current needs and to determine if there are any that are not 
being met. It is anticipated that the results of this study will assist in the medical 
management of individuals with propionic academia.  
 
Are you interested in participating in this study and do I have permission to ask you these 
questions?              
YES                NO 
 
In the first section of this interview, I’ll ask whether or not your child is seen by a variety 
of service providers. If not, I’ll ask why and provide you with optional responses. If yes, 
I’ll ask how old your child was at the first visit, how often your child uses this service, 
and how important this service is to your child’s care. Note that not all of the providers 
and services listed are essential for every child who has propionic academia. 
 
Do you have any questions before we begin?!
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*After the telephone consent script has been read and verbal consent has been obtained and documented.  
 
Before we start the interview, please tell me your relationship to the child.  
__________________________________________________________________________________________________ 
 
What is your child’s age? _____________________________________________________________________________ 
 
At what age was your child diagnosed with propionic academia (PA)? _________________________________________ 
 
The following lists of services and providers are arranged alphabetically.  
 
1.1a Routine Healthcare Providers  !
Does your child see 
the following 
healthcare providers 
and/or services? If no, why not? 
If yes, how old was 
your child at the 
first visit? If yes, how often? 
How important is 
this provider to your 
child’s care? 
Dietitian  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Genetic Counselor 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Geneticist  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed  
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
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Mental health 
therapist 
(eg.psychologist, or 
counselor) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Metabolic Physician 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Nurse 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Nurse Practitioner 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Physical/ 
Rehabilitative 
Medicine  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Very important 
o Somewhat 
important 
o Not important 
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o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
o Every year 
o As needed 
o Other – Specify 
 
Physician’s Assistant 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Primary Care 
Physician (PCP) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Social Worker 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
 
1.1b Are there any additional routine healthcare providers that your child sees? 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.1c What is your level of satisfaction with the care your child received from these routine healthcare providers? 
o Very Satisfied  
o Somewhat Satisfied  
o Neither Satisfied or 
Dissatisfied 
o Somewhat Dissatisfied 
o Very Dissatisfied 
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1.1d What was your personal experience in accessing treatment from these routine healthcare providers? 
o Easy to Access 
o Somewhat Easy to Access 
o Difficult to Access 
o Extremely Difficult to Access
o Is there anything else that you would like to add concerning your personal experience in accessing services?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.1e How well do these routine healthcare providers understand your child's diagnosis of propionic acidemia? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all
 
1.1f How well did these routine healthcare providers incorporate your child's diagnosis of propionic acidemia into 
their clinical management of him/her? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
 
1.1g Were any of these routine healthcare providers especially responsive or unresponsive to your child’s needs? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.1h Is there anything else about your experience with these routine healthcare providers that you would like to 
share?  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.1i Are there any medical needs that your child has that you feel are not being adequately addressed by the 
providers we discussed? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.2a Healthcare Specialty Services !
Does your child see 
the following 
healthcare specialty 
services? If no, why not? 
If yes, how old was 
your child at the 
first visit? If yes, how often? 
How important is 
this service to your 
child’s care? 
Audiology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Very important 
o Somewhat 
important 
o Not important 
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o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
o Every year 
o As needed 
o Other – Specify 
 
Behavioral/ 
Developmental 
Pediatrics  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Cardiology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Dermatology 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability  
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Endocrinology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
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Gastroenterology 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Hematology/ 
Oncology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Nephrology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Neurology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Neuropsychology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Very important 
o Somewhat 
important 
o Not important 
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o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
o Every year 
o As needed 
o Other – Specify 
 
Ophthalmology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Orthopedics 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Otolaryngology 
(ENT: ear, nose, and 
throat) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Psychiatry 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
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Pulmonology  
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Surgery 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Transplant Evaluation 
(kidney, heart, and/or 
liver) 
o Yes  
o No 
 
 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Transplant Reception 
(kidney, heart, and/or 
liver) 
o Yes  
o No 
 
 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
!
1.2b Are there any other healthcare specialty services that provide care for you child? 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 109 
SUBJECT ID #:                                                                                                                      Telephone Interview – Page 9 
 
 
1.2c What is your level of satisfaction with the care your child received from these healthcare specialty services? 
o Very Satisfied  
o Somewhat Satisfied  
o Neither Satisfied or 
Dissatisfied 
o Somewhat Dissatisfied 
o Very Dissatisfied  
 
1.2d What was your personal experience in accessing these healthcare specialty services?
o Easy to Access 
o Somewhat Easy to Access 
o Difficult to Access 
o Extremely Difficult to Access
o Is there anything else that you would like to add concerning your personal experience in accessing services?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.2e How well do these healthcare specialty services understand your child's diagnosis of propionic acidemia? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all
 
1.2f How well did these healthcare specialty services incorporate your child's diagnosis of propionic acidemia into 
their clinical management of him/her? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
 
1.2g Were any of these specialty services especially responsive or unresponsive to your child’s needs? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.2h Is there anything else about your experience with these specialty services that you would like to share?  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.2i Are there any medical needs that your child has that you feel are not being adequately addressed by the 
providers we discussed? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
 
 
1.3a Therapeutic Services  
 
Does your child 
participate in or seek 
help from the 
following? If no, why not? 
If yes, how old was 
your child at the 
first visit? If yes, how often? 
How important is 
this service to your 
child’s care? 
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Occupational Therapy 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical 
insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Physical Therapy 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical 
insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Respiratory Therapy 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical 
insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Speech-language 
Therapy 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical 
insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
!
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1.3b Are there any additional therapeutic services that provide care for your child? 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.3c What is your level of satisfaction with the care your child received from these therapeutic services? 
o Very Satisfied  
o Somewhat Satisfied  
o Neither Satisfied or 
Dissatisfied 
o Somewhat Dissatisfied 
o Very Dissatisfied  
 
1.3d What was your personal experience in accessing these therapeutic services? 
o Easy to Access 
o Somewhat Easy to Access 
o Difficult to Access 
o Extremely Difficult to Access 
o Is there anything else that you would like to add concerning your personal experience in accessing services?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.3e How well do these therapeutic services understand your child's diagnosis of propionic acidemia? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all
 
1.3f How well did these therapeutic services incorporate your child's diagnosis of propionic acidemia into their 
clinical management of him/her? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
 
1.3g Were any of these therapeutic services especially responsive or unresponsive to your child’s needs? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.3h Is there anything else about your experience with these therapeutic services that you would like to share?  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ !
1.3i Are there any medical needs that your child has that you feel are not being adequately addressed by the 
services we discussed? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.4a Home Health Services  
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Does your child 
participate in or 
seek help from the 
following? If no, why not? 
If yes, how old was 
your child at the 
first visit? If yes, how often? 
How important is 
this service to your 
child’s care? 
Home Health Care 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Medical Home 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Religious reason 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Nutritional Services 
(WIC/MAC) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Personal Care 
Attendant (PCA) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Religious reason 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1-3 times/week 
o 1-2 times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
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Public Health Nurse 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Respite Care 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
!
1.4b Are there any additional home health services that your child receives? 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.4c What is your level of satisfaction with the home health services your child receives?  
o Very Satisfied  
o Somewhat Satisfied  
o Neither Satisfied or 
Dissatisfied 
o Somewhat Dissatisfied 
o Very Dissatisfied  !
1.4d What was your personal experience in accessing these home health services? 
o Easy to Access 
o Somewhat Easy to Access 
o Difficult to Access 
o Extremely Difficult to Access 
o Is there anything else that you would like to add concerning your personal experience in accessing services?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.4e How well do these home health services understand your child's diagnosis of propionic acidemia? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all
 
1.4f How well did these home health services incorporate your child's diagnosis of propionic acidemia into their 
management of him/her? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
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1.4g Were any of these home health services especially responsive or unresponsive to your child’s needs? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.4h Is there anything else about your experience with these home health services that you would like to share?  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.4i Are there any medical needs that your child has that you feel are not being adequately addressed by the 
services we discussed? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.5a School Related and Support Services  !
Do you or your child 
participate in or 
seek help from the 
following? If no, why not? 
If yes, how old was 
your child at the 
first visit? If yes, how often? 
How important is 
this service to you 
and your child’s 
care? 
Daycare 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
 
Family Support - 
Other 
o Yes  
o If yes, which one 
______________ 
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
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Head Start 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Preschool 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Social Services 
(County, Medical, 
Developmental 
Disability) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Support groups/self 
help groups related to 
PA 
o Yes  
o If yes, which one 
______________ 
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Every year 
o As needed 
o Other – Specify 
 
o Very important 
o Somewhat 
important 
o Not important 
Waivered Services 
(CAC/CADI waiver, 
other waivers) 
o Yes  
o No 
o Not 
recommended 
o None available 
o Unaware of 
service 
availability 
 o Only one time 
o 1 or more 
times/week 
o 1 or more 
times/month 
o Every 6 months 
o Very important 
o Somewhat 
important 
o Not important 
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o Too expensive 
o Concern about 
medical insurance 
o Child does not 
need this service  
o Other 
o Every year 
o As needed 
o Other – Specify 
 
!
1.5b Are there any additional services that your child receives? 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.5c What is your level of satisfaction with the school related and support services your child receives?  
o Very Satisfied  
o Somewhat Satisfied  
o Neither Satisfied or 
Dissatisfied 
o Somewhat Dissatisfied 
o Very Dissatisfied  
 
1.5d What was your personal experience in accessing these services? 
o Easy to Access 
o Somewhat Easy to Access 
o Difficult to Access 
o Extremely Difficult to Access
o Is there anything else that you would like to add concerning your personal experience in accessing services?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.5e How well do these services understand your child's diagnosis of propionic acidemia? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all
 
1.5f How well did these services incorporate your child's diagnosis of propionic acidemia into their management of 
him/her? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
 
1.5g Were any of these services especially responsive or unresponsive to your child’s needs? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.5h Is there anything else about your experience with these services that you would like to share?  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.5i Are there any medical needs that your child has that you feel are not being adequately addressed by the 
services we discussed? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
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______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.6 How well do you think your child’s various healthcare providers communicate with each other?  
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
o Is there anything else that you would like to add concerning the communication between your child’s healthcare 
providers?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
1.6 Did you discuss the services that you use with your healthcare team?  
o Yes 
o No, why not? Please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
1.7 Did your child spend any time in the newborn intensive care unit?  
o No 
o Yes, for how long?  ______________________________________________________________________________ !
Script:  
 
Now I am going to ask you questions regarding your child’s school experience. Some of these questions will have specific 
answers and other questions will be asking for your opinion.  
 
Do you have any questions before we begin? !
2. Early Intervention Programs and Schooling  
 
1. Did your child receive any pre-school services through early intervention or Child Find programs? 
o No 
o Yes, at what age?  ___ ___ 
 
2. If yes, what was your personal experience in accessing early intervention services? 
o Easy to Access 
o Somewhat Easy to Access 
o Difficult to Access 
o Extremely Difficult to Access 
 
3. If your child did receive pre-school services, what kinds of services were provided? (Choose all that apply) 
o Counseling 
o Educational Instruction 
o Occupational Therapy 
o Physical Therapy 
o Speech Therapy 
o Other 
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4. What is your level of satisfaction with the services that were provided? 
o Very Satisfied  
o Somewhat Satisfied  
o Neither Satisfied or 
Dissatisfied 
o Somewhat Dissatisfied 
o Very Dissatisfied
o Is there anything else that you would like to add concerning your personal experience in accessing services?  
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
 
5. Is your child school aged? 
o No 
o Yes 
 
6. If your child is school aged, what kind of school does he/she attend? 
o Public 
o Private 
o Home-schooled 
o Other (specify): _________________________________________________________________________________ 
 
7. What grade is your child in?  ________________________________________________________________________ 
  
8.  Does your child receive special services? 
o Yes, he/she has IEP (Individualized Education Plan) 
o Yes, he/she has a 504 plan 
o Yes, other (specify): ______________________________________________________________________________ 
o No, he receives no services 
o Unsure 
 
9. In what kind of classrooms does your child work? 
o Regular 
o Special education classes with some main streaming 
o Special education classes with no main streaming 
o Unsure 
 
10. In general, what kind of difficulties, if any, does your child have at school? 
o None 
o Access problems or problems getting around to classes 
o Attention Deficit Disorder 
o Behavior Problems 
o Cognitive Impairment 
o Hyperactivity/Impulsivity 
o Learning Disabilities (specify):  ____________________________________________________________________ 
o Making friends 
o Problems fitting in 
o Other (specify):  _________________________________________________________________________________ 
 
11. If your child does receive services through school what are they? (Choose all that apply) 
o Occupational Therapy 
o Personal Aide 
o Physical Therapy 
o Psychological Services (i.e., counseling, social skills training, behavior management programs) 
o Special Education Services (to address specific learning problems) 
o Speech and Language Therapy 
o Other (specify):  _________________________________________________________________________________
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12. How well does school staff understand your child's diagnosis? 
o Very Well  
o Well  
o Well Enough  
o Not Well  
o Not at all 
 
13. Did the school staff demonstrate an interest in or eagerness to learn about propionic acidemia? 
o Yes, very much so  o Somewhat o Not at all
14. Of the following people outside of the school, who has intervened with the school on behalf of your child so that 
appropriate services could be established or continued? (Choose all that apply) 
o Primary Care Doctor 
o Metabolic Healthcare Provider 
o Mental Health Therapist 
o Nurse 
o Social Worker 
o Special Education Advocate or Consultant 
o Special Education Lawyer 
o None of the above
o Other (specify):  _________________________________________________________________________________ 
 
15. How would you describe the level of support you and your child currently receive from school? 
o Very High  
o High  
o Acceptable  
o Low  
o Very Low 
 
16. At what school level did you experience the most support? 
o Pre-school 
o Elementary (K-6) 
o Middle School (6-8) 
o High School (9-12) 
 
17. At what school level did you experience the least support? 
o Pre-school 
o Elementary (K-6) 
o Middle School (6-8) 
o High School (9-12) 
 
18. Of the following people inside school, who provides support and understanding of your child's needs at school: 
(Choose all that apply) 
o Aide 
o Counselor / Social Worker 
o Occupational Therapist 
o Physical Therapist  
o Principal 
o Resource Teacher 
o School Nurse / Health Aide 
o Speech Therapist 
o Teacher 
o Other (specify): _____________________________
 
19. What has been the most difficult challenge you faced while getting your child through school? 
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
 
20. Do you have any additional comments about your child’s school experience? 
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
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__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
 
21. Are there any medical needs that your child has that you feel are not being adequately addressed by the early 
intervention programs, school services, and school staff? 
o No 
o Yes, please explain:  
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
 
Script:  
 
Now I am going to ask you several questions regarding your family demographics. 
Do you have any questions before we begin? 
 
3. Family Demographics 
 
1. In what type of area is your home located, for example, urban/city, suburban, etc.? 
o Urban 
o Suburban 
o Rural 
o Other (Specify): _________________________________________________________________________________ 
 
2. What is the size of your family? 
 
Number of children:  __________________________________________________________________________ 
 
Number of children with propionic academia: ______________________________________________________ 
 
3. Do you have access to the Internet? 
o No 
o Yes  
 
4. If yes, where do you have access? 
o In your home 
o At work/office 
o At public library 
o Other (Specify):  ________________________________________________________________________________ 
5. Level of education completed for each Parent/Guardian
 
Maternal Education: 
o Unknown 
o 8th grade/less 
o 9th-12th grade, no diploma 
o High school graduate or GED completed 
o Some college credit but no degree 
o Associate degree (e.g., AA, AS) 
o Bachelor's degree (e.g., BA, AB, BS) 
o Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA) 
o Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD) 
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Paternal Education: 
o Unknown 
o 8th grade/less 
o 9th-12th grade, no diploma 
o High school graduate or GED completed 
o Some college credit but no degree 
o Associate degree (e.g., AA, AS) 
o Bachelor's degree (e.g., BA, AB, BS) 
o Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA) 
o Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD) 
 
6. What type of health insurance coverage do you have? 
o None 
o HMO 
o Other managed care plan (including preferred provider organizations (PPO's) and Point of Service (POS) plans). 
o Medicaid/State sponsored programs 
o Military 
o Self-pay 
o Traditional insurance plans (BlueCross / BlueShield, etc.) 
o Don't Know or remember 
o Other (Specify):  ________________________________________________________________________________!!
Closing Script: 
 
Thank you for participating in this telephone interview. Your answers will help us better understand the services and 
resources that are the most useful to patients with propionic acidemia.  
 
If you have any additional questions or comments concerning this study please don’t hesitate to contact myself or Cate 
Walsh Vockley.   
 
My contact information is: 
Phone: (412) 692-6770 
Email: amanda.jacquart@chp.edu 
 
Cate’s Contact information is: 
Phone: (412) 692-7349 
Email: catherine.walshvockley@chp.edu 
 
My contact information as well as Cate’s can also be found on the invitation letter that you received in the mail.  !
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Table 18. Highest Level of Education * Total Number of Health Services Reported Crosstabulation 
 
 Total Number of Health 
Services Reported 
Total 
Less than 
10 
10 to 20 20+ 
Highest Level of 
Education Between 
Mother and Father 
Post-Graduate 
Count 1 1 0 2 
Expected 
Count 
1.3 .3 .3 2.0 
Associate Degree 
to College 
Graduate 
Count 5 0 2 7 
Expected 
Count 
4.7 1.2 1.2 7.0 
9-12 years (no 
diploma) to Some 
College 
Count 2 1 0 3 
Expected 
Count 
2.0 .5 .5 3.0 
Total 
Count 8 2 2 12 
Expected 
Count 
8.0 2.0 2.0 12.0 
 
 
 
Table 19. Highest Level of Education * Total Number of Health Services Reported Fisher’s Exact Test 
 Value df Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Point 
Probability 
Pearson Chi-Square 4.536a 4 .338 .321   
Likelihood Ratio 5.854 4 .210 .265   
Fisher's Exact Test 4.441   .321   
Linear-by-Linear 
Association 
.080b 1 .777 1.000 .486 .181 
N of Valid Cases 12      
a. 9 cells (100.0%) have expected count less than 5. The minimum expected count is .33. 
b. The standardized statistic is -.283. 
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Table 20. Type of Insurance * Total Number of Health Services Reported Crosstabulation 
 Total Number of Health Services 
Reported 
Total 
Less than 
10 
10 to 20 20+ 
Type of 
Insurance 
State/Federal 
Insurance 
(Medicaid/Medicare) 
Count 5 2 2 9 
Expected 
Count 
4.8 1.6 2.6 9.0 
Commercial/Private 
Insurance 
Count 4 1 3 8 
Expected 
Count 
4.2 1.4 2.4 8.0 
Total 
Count 9 3 5 17 
Expected 
Count 
9.0 3.0 5.0 17.0 
 
 
 
 
 
Table 21. Type of Insurance * Total Number of Health Services Reported Fisher’s Exact Test 
 Value df Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Point 
Probability 
Pearson Chi-Square .588a 2 .745 1.000   
Likelihood Ratio .594 2 .743 1.000   
Fisher's Exact Test .754   1.000   
Linear-by-Linear 
Association 
.225b 1 .635 .793 .419 .190 
N of Valid Cases 17      
a. 6 cells (100.0%) have expected count less than 5. The minimum expected count is 1.41. 
b. The standardized statistic is .475. 
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WILCOXON RANK-SUM TEST 
Table 22. Days of Age from Birth to Initiation of Intervention Mean Rank by Diagnosis Method 
 
 Diagnosis Method N Mean Rank Sum of Ranks 
Days of Age from Birth to 
Initiation of Intervention 
Abnormal NBS 10 11.55 115.50 
Clinical Presentation 18 16.14 290.50 
Total 28   
 
 
 
Table 23. Days of Age from Birth to Initiation of Intervention Rank Test Statistics 
 Days of Age from 
Birth to Initiation 
of Intervention 
Mann-Whitney U 60.500 
Wilcoxon W 115.500 
Z -1.419 
Asymp. Sig. (2-tailed) .156 
Exact Sig. [2*(1-tailed Sig.)] .160b 
a. Grouping Variable: Diagnosis Method 
b. Not corrected for ties. 
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Table 24. Days of Age at Time of Initial Face-to-Face Metabolic Consultation Mean Rank by Diagnosis Method 
 Diagnosis Method N Mean Rank Sum of Ranks 
Days of Age at Time of Initial 
Face-to-Face Metabolic 
Consultation 
Abnormal NBS 10 12.05 120.50 
Clinical Presentation 18 15.86 285.50 
Total 28   
 
 
 
Table 25. Days of Age at Time of Initial Face-to-Face Metabolic Consultation Rank Test Statistics 
 Days of Age at 
Time of Initial 
Face-to-Face 
Metabolic 
Consultation 
Mann-Whitney U 65.500 
Wilcoxon W 120.500 
Z -1.177 
Asymp. Sig. (2-tailed) .239 
Exact Sig. [2*(1-tailed Sig.)] .245b 
a. Grouping Variable: Diagnosis Method 
b. Not corrected for ties. 
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VARIABILITY OBSERVED IN THE NUMBER OF TIMES OTHER HEALTH 
SERVICES WERE REPORTED PER “FOLLOW-UP” SUBJECT 
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 Number of Times Reported Per Subject   
Other Health Services 
Received Currently 1 2 3 4 5 6 7 8 9 10 12 16 
Number of 
Subjects 
Total 
Number 
Reported 
Audiology 0 0 1 0 0 0 0 0 0 0 0 0 1 3 
Behavioral/Developmental 
Pediatrics 1 0 0 0 0 0 0 0 0 0 0 0 1 1 
Cardiology 0 4 2 1 2 0 0 0 1 1 1 0 12 59 
Dentistry 0 1 0 0 1 0 0 0 0 0 0 0 2 7 
Dietitian 2 1 1 1 0 0 0 0 0 0 0 0 5 11 
Feeding Therapy 1 0 0 0 0 0 0 0 0 0 0 0 1 1 
Gastroenterology 0 0 0 0 1 0 0 0 0 0 0 0 1 5 
Hematology 2 0 0 0 0 0 0 0 0 0 0 0 2 2 
Home Health Care 1 0 0 0 0 0 0 0 0 0 0 0 1 1 
Nephrology 1 1 0 0 0 0 0 0 0 0 0 0 2 3 
Neurology 2 2 1 0 1 0 0 0 0 0 0 1 7 30 
None 4 1 0 0 0 0 0 1 0 0 0 0 6 14 
Occupational Therapy 1 0 1 0 2 0 1 0 0 0 0 1 6 37 
Ophthalmology 0 2 2 0 1 1 0 0 0 0 0 0 6 21 
Orthopedics 0 1 0 0 1 0 0 0 0 0 0 0 2 7 
Other 1 0 1 0 0 0 0 0 0 0 0 0 2 4 
Physical Therapy 1 1 1 0 1 0 1 0 0 0 0 1 6 34 
Preschool 0 1 0 0 0 0 0 0 0 0 0 0 1 2 
Primary Care Provider 4 0 0 0 0 0 0 0 0 0 0 0 4 4 
Pulmonology 1 0 0 0 1 0 0 0 0 0 0 0 2 6 
Speech-Language Therapy 0 0 3 0 1 0 0 1 0 0 0 0 5 22 
Surgery 1 0 0 0 0 0 0 0 0 0 0 0 1 1 
Urology 1 0 0 0 0 0 0 0 0 0 0 0 1 1 
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VARIABILITY OBSERVED IN THE NUMBER OF TIMES COMMUNITY 
RESOURCES WERE REPORTED PER “FOLLOW-UP” SUBJECT 
 
 
 
Number of Times Reported 
Per Subject 
  Community Resources 
Received Currently 1 2 3 4 5 6 7 8 
Number of 
Subjects 
Total Number 
Reported 
Daycare 0 0 0 0 1 0 0 0 1 5 
Family Support - Other 0 1 0 0 0 0 0 0 1 2 
Family Support Group 
Related to this IBEM 0 1 0 0 0 0 0 0 1 2 
Head Start 0 1 0 0 0 0 0 0 1 2 
None 2 4 2 0 0 0 1 1 10 31 
Nutritional Services 
(WIC/MAC) 2 1 0 0 0 0 0 0 3 4 
Other 2 0 0 1 0 0 0 0 3 6 
Preschool 1 1 0 0 1 0 0 0 3 8 
Social Services - County 0 1 0 0 0 0 0 0 1 2 
Social Services - 
Developmental disability 0 0 1 0 1 0 0 0 2 8 
Social Services - Medical 2 0 0 1 0 0 0 0 3 6 
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APPENDIX O 
VARIABILITY OBSERVED IN THE NUMBER OF TIMES PROVIDERS WERE 
REPORTED PER “FOLLOW-UP” SUBJECT 
 
 
 
 Number of Times Reported Per Subject   
Providers 
Seen at this 
Visit 
1 2 3 4 5 6 7 8 9 10 11 12 18 19 Number of Subjects 
Total 
Number 
Reported 
Dietitian 2 5 4 0 2 0 0 1 1 2 0 0 1 0 18 89 
Genetic 
Counselor 2 1 1 0 0 0 0 0 0 1 0 0 0 0 5 17 
Nurse 6 1 0 0 1 0 0 0 0 0 0 0 0 0 8 13 
Nurse 
Practitioner 0 1 2 1 0 0 0 0 0 0 0 0 0 0 4 12 
Physician 2 6 4 0 1 0 1 0 0 3 0 0 0 1 18 87 
Social 
Worker 2 1 0 0 0 1 0 0 0 0 0 0 0 0 4 10 
 
 131 
BIBLIOGRAPHY 
Alberola, T. M., R. Bautista-Llacer, X. Vendrell, E. Garcia-Mengual, M. Pardo, M. Vila and C. 
Calatayud (2011). "Case report: birth of healthy twins after preimplantation genetic 
diagnosis of propionic acidemia." J Assist Reprod Genet 28(3): 211-216. 
Bailey, D. B., M. Raspa and M. G. Olmsted (2010). "Using a parent survey to advance 
knowledge about the nature and consequences of fragile X syndrome." Am J Intellect 
Dev Disabil 115(6): 447-460. 
Berry, S. A., A. M. Jurek , C. Anderson and K. Bentler (2010). "The inborn errors of metabolism 
information system: A project of the Region 4 Genetics Collaborative Priority 2 
Workgroup." Genetics in Medicine 12. 
Bultron, G., M. R. Seashore, D. S. Pashankar and S. Z. Husain (2008). "Recurrent acute 
pancreatitis associated with propionic acidemia." J Pediatr Gastroenterol Nutr 47(3): 370-
371. 
Burton, B. K. (1998). "Inborn errors of metabolism in infancy: a guide to diagnosis." Pediatrics 
102(6): E69. 
Chapman, K., A. Gropman, E. MacLeod, K. Stagni, M. Summar, K. Ueda, N. Ah Mew, J. 
Franks, E. Island, D. Matern, L. Pena, B. Smith, V. Sutton, T. Urv, C. Venditti and A. 
Chakrapani (2012). "Acute management of propionic acidemia." Mol Genet Metab 
105(1): 16-25. 
Chapman, K. and M. Summar (2012). "Propionic acidemia consensus conference summary." 
Mol Genet Metab 105(1): 3-4. 
Childs, B., W. L. Nyhan, M. Borden, L. Bard and R. E. Cooke (1961). "Idiopathic 
hyperglycinemia and hyperglycinuria: a new disorder of amino acid metabolism. I." 
Pediatrics 27: 522-538. 
Desviat, L., B. Pérez, C. Pérez-Cerdá, P. Rodríguez-Pombo, S. Clavero and M. Ugarte (2004). 
"Propionic acidemia: mutation update and functional and structural effects of the variant 
alleles." Mol Genet Metab 83(1-2): 28-37. 
Desviat, L. R., S. Clavero, C. Perez-Cerda, R. Navarrete, M. Ugarte and B. Perez (2006). "New 
splicing mutations in propionic acidemia." J Hum Genet 51(11): 992-997. 
Desviat, L. R., R. Sanchez-Alcudia, B. Perez, C. Perez-Cerda, R. Navarrete, R. Vijzelaar and M. 
Ugarte (2009). "High frequency of large genomic deletions in the PCCA gene causing 
propionic acidemia." Mol Genet Metab 96(4): 171-176. 
 132 
Dionisi-Vici, C., F. Deodato, W. Röschinger, W. Rhead and B. Wilcken (2006). "'Classical' 
organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: 
long-term outcome and effects of expanded newborn screening using tandem mass 
spectrometry." Journal of inherited metabolic disease 29(2-3): 383-389. 
Griggs, R., M. Batshaw, M. Dunkle, R. Gopal-Srivastava, E. Kaye, J. Krischer, T. Nguyen, K. 
Paulus, P. Merkel and N. Rare Diseases Clinical Research (2009). "Clinical research for 
rare disease: opportunities, challenges, and solutions." Molecular genetics and 
metabolism 96(1): 20-26. 
Grünert, S., S. Müllerleile, L. De Silva, M. Barth, M. Walter, K. Walter, T. Meissner, M. 
Lindner, R. Ensenauer, R. Santer, O. Bodamer, M. Baumgartner, M. Brunner-Krainz, D. 
Karall, C. Haase, I. Knerr, T. Marquardt, J. Hennermann, R. Steinfeld, S. Beblo, H.-G. 
Koch, V. Konstantopoulou, S. Scholl-Bürgi, A. van Teeffelen-Heithoff, T. Suormala, W. 
Sperl, J. Kraus, A. Superti-Furga, K. Schwab and J. Sass (2013). "Propionic acidemia: 
clinical course and outcome in 55 pediatric and adolescent patients." Orphanet journal of 
rare diseases 8: 6. 
Grunert, S. C., S. Mullerleile, L. de Silva, M. Barth, M. Walter, K. Walter, T. Meissner, M. 
Lindner, R. Ensenauer, R. Santer, O. A. Bodamer, M. R. Baumgartner, M. Brunner-
Krainz, D. Karall, C. Haase, I. Knerr, T. Marquardt, J. B. Hennermann, R. Steinfeld, S. 
Beblo, H. G. Koch, V. Konstantopoulou, S. Scholl-Burgi, A. van Teeffelen-Heithoff, T. 
Suormala, W. Sperl, J. P. Kraus, A. Superti-Furga, K. O. Schwab and J. O. Sass (2012). 
"Propionic acidemia: neonatal versus selective metabolic screening." J Inherit Metab Dis 
35(1): 41-49. 
Haberlandt, E., C. Canestrini, M. Brunner-Krainz, D. Möslinger, K. Mussner, B. Plecko, S. 
Scholl-Bürgi, W. Sperl, K. Rostásy and D. Karall (2009). "Epilepsy in patients with 
propionic acidemia." Neuropediatrics 40(3): 120-125. 
Jameson, E. and J. Walter (2008). "Cardiac arrest secondary to long QT(C )in a child with 
propionic acidemia." Pediatr Cardiol 29(5): 969-970. 
Lam, C., L. R. Desviat, C. Perez-Cerda, M. Ugarte, B. A. Barshop and S. Cederbaum (2011). 
"45-Year-old female with propionic acidemia, renal failure, and premature ovarian 
failure; late complications of propionic acidemia?" Mol Genet Metab 103(4): 338-340. 
Magdalena, U., P. r.-C. Celia, R. g.-P. Pilar, R. D. Lourdes, P. r. Bel n, R. Eva, M. Silvia, C. 
Eric, O. Toshihiro and A. G. Roy (1999). "Overview of mutations in thePCCA andPCCB 
genes causing propionic acidemia." Human Mutation 14. 
Mardach, R., M. Verity and S. Cederbaum (2005). "Clinical, pathological, and biochemical 
studies in a patient with propionic acidemia and fatal cardiomyopathy." Molecular 
genetics and metabolism 85(4): 286-290. 
Marsolo, K. (2012). "Approaches to facilitate institutional review board approval of multicenter 
research studies." Med Care 50 Suppl: S77-81. 
 133 
Muro, S., B. Pérez, L. Desviat, P. Rodríguez-Pombo, C. Pérez-Cerdá, S. Clavero and M. Ugarte 
(2001). "Effect of PCCB gene mutations on the heteromeric and homomeric assembly of 
propionyl-CoA carboxylase." Mol Genet Metab 74(4): 476-483. 
Patel, M. X. (2003). "Challenges in recruitment of research participants." Advances in 
Psychiatric Treatment 9. 
Pena, L. and B. Burton (2012). "Survey of health status and complications among propionic 
acidemia patients." American journal of medical genetics. Part A 158A(7): 1641-1646. 
Pena, L., J. Franks, K. A. Chapman, A. Gropman, N. Ah Mew, A. Chakrapani, E. Island, E. 
MacLeod, D. Matern, B. Smith, K. Stagni, V. R. Sutton, K. Ueda, T. Urv, C. Venditti, G. 
M. Enns and M. L. Summar (2012). "Natural history of propionic acidemia." Mol Genet 
Metab 105(1): 5-9. 
Perez-Cerda, C., B. Merinero, P. Rodriguez-Pombo, B. Perez, L. R. Desviat, S. Muro, E. 
Richard, M. J. Garcia, J. Gangoiti, P. Ruiz Sala, P. Sanz, P. Briones, A. Ribes, M. 
Martinez-Pardo, J. Campistol, M. Perez, R. Lama, M. L. Murga, T. Lema-Garrett, A. 
Verdu and M. Ugarte (2000). "Potential relationship between genotype and clinical 
outcome in propionic acidaemia patients." Eur J Hum Genet 8(3): 187-194. 
Perez-Cerda, C., B. Perez, B. Merinero, L. R. Desviat, P. Rodriguez-Pombo and M. Ugarte 
(2004). "Prenatal diagnosis of propionic acidemia." Prenat Diagn 24(12): 962-964. 
Peters-Lawrence, M., M. Bell, L. Hsu, I. Osunkwo, P. Seaman, M. Blackwood, E. Guillaume, R. 
Bellevue, L. Krishnamurti, W. Smith, C. Dampier, C. Minniti and N. Sickle Cell Disease 
Clinical Research (2012). "Clinical trial implementation and recruitment: lessons learned 
from the early closure of a randomized clinical trial." Contemporary clinical trials 33(2): 
291-297. 
Sanchez-Alcudia, R., B. Perez, M. Ugarte and L. R. Desviat (2012). "Feasibility of nonsense 
mutation readthrough as a novel therapeutical approach in propionic acidemia." Hum 
Mutat 33(6): 973-980. 
Sass, J. O., M. Hofmann, D. Skladal, E. Mayatepek, B. Schwahn and W. Sperl (2004). 
"Propionic acidemia revisited: a workshop report." Clin Pediatr (Phila) 43(9): 837-843. 
Sibbald, B., J. Addington-Hall, D. Brenneman and P. Freeling (1994). "Telephone versus postal 
surveys of general practitioners: methodological considerations." Br J Gen Pract 44(384): 
297-300. 
Sindgikar, S. P., S. Rao, R. D. Shenoy and N. Kamath (2013). "Biochemical basis of 
heterogeneity in acute presentations of propionic acidemia." Indian J Clin Biochem 
28(1): 95-97. 
Strauss, K. A. and E. G. Puffenberger (2009). "Genetics, medicine, and the Plain people." Annu 
Rev Genomics Hum Genet 10: 513-536. 
 134 
Sutton, V. R., K. A. Chapman, A. L. Gropman, E. MacLeod, K. Stagni, M. L. Summar, K. Ueda, 
N. Ah Mew, J. Franks, E. Island, D. Matern, L. Pena, B. Smith, T. Urv, C. Venditti and 
A. Chakarapani (2012). "Chronic management and health supervision of individuals with 
propionic acidemia." Mol Genet Metab 105(1): 26-33. 
Tahara, T., J. P. Kraus, T. Ohura, L. E. Rosenberg and W. A. Fenton (1993). "Three independent 
mutations in the same exon of the PCCB gene: differences between Caucasian and 
Japanese propionic acidaemia." J Inherit Metab Dis 16(2): 353-360. 
Ugarte, M., C. Perez-Cerda, P. Rodriguez-Pombo, L. R. Desviat, B. Perez, E. Richard, S. Muro, 
E. Campeau, T. Ohura and R. A. Gravel (1999). "Overview of mutations in the PCCA 
and PCCB genes causing propionic acidemia." Hum Mutat 14(4): 275-282. 
Uhlmann, W. R., J. L. Schuette, B. M. Yashar and ebrary Inc. (2009). A guide to genetic 
counseling. Hoboken, N.J., Wiley-Blackwell,: xxii, 624 p. 
Williams, Z. R., P. E. Hurley, U. E. Altiparmak, S. E. Feldon, G. L. Arnold, E. Eggenberger and 
L. J. Mejico (2009). "Late onset optic neuropathy in methylmalonic and propionic 
acidemia." Am J Ophthalmol 147(5): 929-933. 
Wolf, B., E. P. Paulsen and Y. E. Hsia (1979). "Asymptomatic propionyl CoA carboxylase 
deficiency in a 13-year-old girl." J Pediatr 95(4): 563-565. 
Yorifuji, T., M. Kawai, J. Muroi, M. Mamada, K. Kurokawa, Y. Shigematsu, S. Hirano, N. 
Sakura, I. Yoshida, T. Kuhara, F. Endo, H. Mitsubuchi and T. Nakahata (2002). 
"Unexpectedly high prevalence of the mild form of propionic acidemia in Japan: 
presence of a common mutation and possible clinical implications." Human genetics 
111(2): 161-165. 
 
